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Abstract
Decreased Triiodothyronine Binding to the Hepatic Nuclear
Thyroid Hormone Receptor in the Diabetic Mouse
by
Thomas J. DeWind
The diabetic C57BL/KsJ-djb m mouse has abnormal
thyroid hormone levels and indications of thyroid hormone
resistance.

To investigate the basis of these

abnormalities, the hepatic nuclear thyroid hormone
receptor was extracted with 0.4 M KC1, 1.1 mM MgCl2/ 20 mM
Tris/HCl, pH 7.9 from hepatocyte nuclei of normal
C57BL/KsJ, heterozygous C57BL/KsJ-db m (db/m), and
diabetic C57BL/KsJ-db m (db/db) mice,

Normal and

heterozygous mice were grouped together as the controls.
Triiodothyronine (T3) binding studies at 4°C using
nitrocellulose filtration to separate free T3 from
receptor bound T3 demonstrated an apparent dissociation
constant of (1.3 ± 0.8) x 10 -10 M for controls which was
significantly less than that of (8.7 ± 10.4) x 10 -10 M for
diabetic mice (p<0.01, one tailed t-test).

However, the

maximum binding capacities were not significantly
different at (4.6 ± 3.3) x 10 -13 moles/mg DNA for controls
and (3.2 ± 4.6) x 10 -13 moles/mg DNA for diabetic mice.
Triiodothyronine-receptor dissociation rates also

demonstrated a significantly greater dissociation of the
diabetic T3-receptor complex (p<0.05, one-tailed t-test).
The half-life for dissociation was 101 ± 22 hours for
controls versus 70 ± 21 hours for diabetics.

Although

equilibrium binding conditions were not achieved, the use
of Scatchard analysis to compare the controls and
diabetics is justified by the similar conclusion from
dissociation experiments that T3 binding is significantly
decreased in the diabetic mouse.

Triiodothyronine was

found to interact freely with the receptor, binding 98 ±
2% of that predicted to be bound if T3 were free in
solution, even though 70 ± 2% of the T3 is initially
adsorbed to the glassware.

However, adsorption to

glassware did explain the negative values for specific
binding above 10”6 M T3 as calculated from the difference
between total and nonspecific binding.

Isoelectric

focusing and sedimentation velocity of the receptor
preparation did not demonstrate any differences between
control and diabetic mice.

Comparison of the level of

saturation of the nuclear T3 receptor in the diabetic
mouse to other obese syndromes suggests that the decreased
T3 binding reported here has a significant impact on the
obesity of the diabetic mouse.
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1.
1.1

Thyroid Hormones

1.1.1

History

Introduction

Thyroid hormones were isolated in 1914 by E. C.
Kendall.

Although he was able to crystalize them, their

chemical nature was unknown.

In 1927 Harington and Barger

synthesized thyroxine (T4) and showed it to be the major
component released from the thyroid gland.

In 1952

triiodothyronine (T3) was synthesized and shown to be
another important molecule mediating thyroid effects
(Gross & Pitt-Rivers, 1953).

The conversion of T4 to T3

in peripheral tissue was demonstrated by Sterling in 1970.
In spite of decades of study, many aspects of thyroid
hormone action remain unknown.

Although thyroid

physiology is generally well established, the mechanism of
hormone transport to its receptor, the relative importance
of T4 versus T3, the cellular location of the receptor,
and the control of the hormonal response all still remain
to be fully elucidated.
1.1.2

Thyroid Gland Physiology
The thyroid gland contains the majority of the iodine

found in the body,

Iodide from the diet is actively

concentrated in the thyroid gland where it is oxidized to
elemental iodine by thyroperoxidase.

Free radicals of the

tyrosine residues in thyroglobulin molecules and of the

1
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iodine atom then combine at the active site of
thyroperoxidase to form monoiodotyrosine and
diiodotyrosine.

Thyroperoxidase is also involved in the

coupling of monoiodotyrosine and diiodotyrosine to form T3
and T4 dipeptide derivatives in thyroglobulin.

These

iodinated residues in thyroglobulin are stored in
follicles in an aggregation called colloid until thyroid
hormone is required.

Endocytosis of colloid followed by

fusion with lysosomes leads to proteolytic enzymatic
cleavage of thyroglobulin yielding the active forms of
thyroid hormones which are then released into the blood
stream.
Circulating thyroxine-binding globulin (TBG) binds
more than three-fourths of the thyroid hormone released.
Thyroxine-binding prealbumin (TBPA) and serum albumin also
bind thyroid hormone so that only 0.3% of T3 and 0.03% of
T4 remains unbound and freely diffusible.
The half-life of T4 in plasma is 6 days while that of
T3 is less than 1 day.

The liver is the major site of

thyroid hormone inactivation.

There T3 and T4 combine

with glucuronic acid and the conjugates formed are
excreted in the bile.

In the intestine, bacteria cleave

the conjugates to release the hormones which may then be
reabsorbed into the blood stream.

Thus, within the

intestinal lumen 30% of the T4 and 75% of the T3 pools are

3
present in a form that is available to buffer plasma
hormone levels (DiStefano et al., 1986).

Inactivation of

thyroid hormones also occurs through extrathyroidal
deiodination and deamination.
1.1.3

The Effects of Thyroid Hormone
Thyroid hormones have a wide range of effects on

vertebrates.

Triiodothyronine stimulates cell

replication, differentiation, development, thermogenesis,
and 02 consumption.

Triiodothyronine regulates some

enzyme levels and a2u-globulin production.

It also

induces catecholamine receptor synthesis, stimulates
mammary gland function, stimulates growth hormone
production, and inhibits production and secretion of
thyrotropin (TSH) and prolactin (Samuels, 1983).

The

effects of thyroid hormones on growth appear to be
mediated through their effects on increasing growth
hormone secretion and effectiveness (Schwartz, 1983).
Some of the effects of thyroid hormones are species
or even tissue specific.

Amphibians require thyroid

hormones to undergo metamorphosis (Galton, 1983).

During

tadpole metamorphosis, the maximum binding capacity (MBC)
for T3 increases in erythrocytes, although not in
hepatocyte nuclei.

This increase is speculated to be

involved in controlling tissue specific cell destruction
(Galton & Germain, 1985).

Thus, in lower vertebrates

4 .
thyroid hormones seem to be involved primarily in
development (Weirich et al., 1987).
1.1.3.1

Development and Maturation

Although thyroid hormones are present in the fetus,
they are not required prior to birth (Schwartz, 1983).
Even after birth they are not required to maintain life;
however, they are required for normal post-natal
development.

Hamburgh et al. (1971) proposed that thyroid

hormones act to switch cells from a state of proliferation
to one of differentiation.

Consistent with this

hypothesis, thyroid hormones are required for skeletal
maturation and for brain development.
Although thyroid hormones are not necessary prior to
birth, they must be present immediately after birth to
have proper development.

T3 treatment at 2 months of age

is too late to restore completely normal development
(Schwartz, 1983).

Replacement T3 is needed in the rat

within 10 days after birth to avoid permanent
developmental damage.
Respiratory distress syndrome may also be related to
low thyroid hormone levels.

Since both T3 and

glucocorticoids appear to initiate the differentiation of
lung, it may be necessary that both be diminished to have
respiratory distress syndrome (Schwartz, 1983; Ikegami et
al., 1987).

In general, if an animal is hypothyroid at
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the time of birth, a critical post natal period of
hormone-dependent biochemical maturation may be missed.
1.1.3.2

Ribonucleic Acid (RNA)

One of the most widely reported effects of T3 is that
of influencing the production of specific RNAs.

Dozin et

al. (1985c) showed an 11 fold increase in the messenger
RNA (mRNA) for malic enzyme after injecting rats with
saturating levels of T3.

Fatty acid synthetase, acetyl-

CoA carboxylase, ATP-citrate lyase, glucose-6-phosphate
dehydrogenase, 6-phosphogluconate dehydrogenase, growth
hormone, a2u-globulin, and carbamoyl-phosphate synthetase
I mRNAs are also known to be increased by increased T3
levels (Bismuth et al., 1985; Dozin et al., 1985c).
Triiodothyronine alters the levels of 19 of the 230
rat hepatic mRNAs that can be followed by a mRNA dependent
translation system.

This system generates 35S-labeled

proteins which can be separated by two-dimensional gel
electrophoresis.

The levels of 11 mRNAs are increased in

parallel with T 3' 7 are decreased, and 1 is biphasic.
These effects may be direct or indirect. For example, the
T3 stimulation of growth hormone production explains the
effects seen on 6 of the mRNAs (Towle, 1983).

Magnuson et

al. (1985) strengthened the correlation between T3 levels
and mRNA levels by reporting that growth hormone mRNA
levels are proportional to the nuclear T3 receptor

6
occupancy.

On the other hand, a-glycerophosphate

dehydrogenase and hepatic malic enzyme mRNAs do not
demonstrate a linear relationship.
In addition to increased RNA levels, all classes of
RNA polymerase have increased activity after exposure to
t3.

Hepatocyte nuclear RNA polymerase activity is

elevated within 3-6 hours after T3 administration (Barsano
& DeGroot, 1983).

This increase in activity is due to an

increased amount of polymerase.
1.1.3.3

Heat Production

One of the first theories for the mechanism of
stimulating cellular heat production proposed that thyroid
hormones uncouple oxidative phosphorylation.

However,

this hypothesis has been abandoned due to several
inconsistencies found in later experimental work.

First,

biologically inactive iodinated compounds also cause
uncoupling.

Second, other uncouplers could not reproduce

the effects of T3.

Finally, with physiological doses of

T3 the ratio of inorganic phosphate incorporated per atom
of oxygen consumed remained normal (Guernsey & Edelman,
1983) .
The thermogenic response now appears to be primarily
due to energy expended on increased sodium and potassium
transport.

This increase in ion transport in turn is due

to an increased biosynthesis of the Na+-K+-ATPase
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(Guernsey & Edelman, 1983; Towle, 1983).

To a lesser

extent, thermogenesis is the result of an increase in
futile cycling where both biosynthetic and degradative
pathways are stimulated by T3.
1.1.3.4

Adrenergic-Type Effects

Some effects of T3 mimic or supplement those of
(3-adrenergic stimulation.

T3 influences the adrenergic

modulation of lipolysis (Williams & Lefkowitz, 1983).
Conversely, blocking p-adrenergic events reduces the
symptoms of thyrotoxicosis.
The heart demonstrates significant ties between T3
and adrenergic-type effects.

Triiodothyronine

administration leads to sinus tachycardia and increased
contractility in the same way as does sympathetic
stimulation.

In addition, T3 increases the number of

cardiac p-adrenergic receptors while decreasing the number
of a-adrenergic receptors (Williams & Lefkowitz, 1983?
Towle, 1983).

Although some of the effects of T3 and

adrenergic stimulation are identical, T3 does not have its
effect at the p-adrenergic receptor,

Neither does

adrenergic stimulation lead to hyperthyroidism,

Thus, the

link between thyroid hormones and adrenergic stimulation
remains to be elucidated.
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1.1.3.5

Endoplasmic Reticulum Effects

Triiodothyronine is required to maintain normal
hepatic endoplasmic reticulum (Roy, 1983).

Growth hormone

can partially normalize a2u-globulin mRNA levels but T3 is
required to fully restore the level of a2U~globulin
protein to normal (a2u-globulin is the major protein in
the urine of male rats).

Thus, one proposed effect of T3

is to keep endoplasmic reticulum functioning normally.
thereby allowing a2u-globulin to be exported before it is
degraded.
1.1.4

Deiodination of Thyroxine
In man 83% of T3 is derived from non-thyroidal

deiodination of T4 (Oppenheimer, 1983).

This conversion

is important in that T3 has 3-5 times greater biological
activity than T4.

Since there is 3-5 times less T3 than

T4, both exert an equal effect.
1.1.4.1

Deiodinase Types

There are two 51-monodeiodination enzymes (McNabb et
al., 1986).

The type I 5'-monodeiodinase has a

for T4

of 5 pH and is present in liver, kidney, and many other
organs.

The type II deiodinase is important in supplying

intracellular T3 (Tanaka et al., 1987).

It has a

for

T4 of 3 nM and is located in brain, anterior pituitary,
placenta, and brown adipose tissue,

In brown adipose

tissue the intracellular conversion of T4 to T3 is
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required for optimal thermogenic function (Blanco & Silva,
1987) .
1.1.4.2

The Significance of the T3/T4 Ratio

Wilkin and Isles (1984) studied serum T3 and T4
levels in euthyroid man and found the natural variations
in T3 levels to be independent of T4 levels.

However, the

T3/T4 ratio seemed to buffer the variation in T4.

They

concluded that a relatively constant level of thyroid
hormone effects is achieved over a wide range of T4 values
by alterations in the T3/T4 ratio.
1.1.4.3

Factors Affecting the Deiodination of T4

T4 to T3 conversion is increased by the availability
of carbohydrate in the diet (Mariash & Oppenheimer, 1983;
Schalch & Cree, 1985).

Conversion is also increased by

elevated levels of reduced sulfhydryls (Smith & Eastman,
1980).

The sex hormones have some effects as well.

Female rats approaching puberty show a decrease in T3
synthesis not seen in males (Harris et al., 1979).

In the

pineal gland, the T4 deiodinase follows a circadian rhythm
defined by p-adrenergic stimulation (Tanaka et al., 1987).
Thyroid hormones are also responsive to cold exposure with
the T3/T4 ratio increasing more than 2-fold in rats
exposed to cold.

This adaptive change is mediated through

the sympathetic nervous system (Guernsey & Edelman, 1983;
Rudas & Pethes, 1986) .

Genetically obese mice will die in

10
the cold due to an inability to stimulate their
5'-deiodinase, thus illustrating the significance of this
adaptation.
1.1.5

T3 Transport

1.1.5.1

Serum T3 Transport

Over 99% of the T3 and T4 are transported in the
blood bound to plasma proteins.

The level of free T3 is

thought to be about 6 x 10 -12 M in euthyroid animals with
a serum binding Ka of 1.6 x 1011 M”1.

Ordinarily it is

the free fraction of a hormone that is thought to be
biologically active; however, the concept of free hormone
may not apply to thyroid hormones.

Instead, there is a

"collisional transfer theory" for thyroid hormones in
which T3 is directly transferred between proteins in a
manner that mimics the existence of a small free fraction
in solution (Oppenheimer, 1983).

According to this

theory, a large number of low affinity sites would bind
most of the thyroid hormone and act to transport and
buffer the supply.

A few high affinity sites would then

pick up T3 from the low affinity sites and lead to the
effects of thyroid hormone.

In support of this theory, no

lowering of the "free" hormone concentration resulted from
the dilution of serum (Samuels, 1983), although with
dilution, protein bound T3 would be expected to buffer the
free T3 level.

11 .
1.1.5.2

Cytoplasmic T3 Transport

Originally, the uptake of T3 into cells was thought
to be entirely due to diffusion (Surks et al., 1975).
However, the levels of T3 binding in the cell indicate
that either free T3 has been underestimated by equilibrium
dialysis, or the cytoplasmic T3 levels are 10-fold higher
than that in plasma (Oppenheimer, 1983).
Active uptake of T3 into cells seems reasonable in
light of the presence of T3 binding sites in the plasma
membrane (Horiuchi et al., 1982b; Cheng, 1983? Casanova et
al., 1984? Dozin et al., 1985b; Pontecorvi et al., 1987).
Horiuchi et al. (1982a) found that the addition of
monodansylcadaverine (which blocks receptor mediated
endocytosis) blocks the uptake of T3 and its accumulation
in the nucleus.
Intracellular binding sites for T3 have been
described by Defer et al. (1975) .

Barsano and DeGroot

(1983) described a group of cytosolic T3 binding proteins
having 170 times the binding capacity of the nuclear
binding proteins, but which are only 1% occupied,

Lennon

et al. (1983) saw similar high affinity binding sites in
the cytosol of brain cells in culture,

Both high and low

affinity sites were seen having Ka's for T3 of 1.2 - 3.7 x
109 M”1 and 0.8

1.4 x 108 M-1.

The low affinity sites

are thought to be involved in the storage and transport of

12
T3/ but the role of the high affinity sites is uncertain.
In contrast to the above findings, Samuels and Tsai (1973)
in an earlier examination of GH-^ cells did not find any
evidence of cytosolic binding sites.
Further evidence for the involvement of some type of
transport into the cell can be seen in the study of
Halpern and Hinkle (1982) and Hashizume et al. (1987).
Several drugs studied could slow T3 uptake into whole
cells, but not into isolated nuclei,

Cytochalasin b (a

microfilament disrupter), chloroquine (a lysosomal
inhibitor), and dansylcadaverine (an inhibitor of
transglutaminase) all inhibit the uptake of T3 into whole
cells.
1.1.5.3

Nuclear T3 Transport

Surks et al. (1975) demonstrated that neither a
cytoplasmic carrier nor energy metabolism was required to
move T3 into the nucleus,

However, they did note that the

apparent affinity of the purified receptor for T3 in vitro
was 1000-fold less than for cells in vivo.

Oppenheimer

(1985) later showed that there in fact is a stereospecific
(D-L) energy dependent transport system that translocates
T3 from the cytosol to the nucleus, although antimycin A
blocks the nuclear uptake of T3 by a mechanism other than
by inhibition of ATP synthesis (Valdivielso & Bernal,
1987) .

The presence of this transport system would
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explain why less D-T3 is found in the nucleus than L-T3
even though D-T3 has a higher affinity for the nuclear
receptor.
Venkatraman and Lefebvre (1985) described two classes
of binding sites in rat liver nuclear membranes which
might be involved in T3 translocation.

One has a

dissociation constant (Kd) of 1.8 nM and a maximum binding
capacity (MBC) of 14.5 pmol/mg protein, the other has a Kd
of 152.1 nM and a MBC of 346.8 pmol/mg protein.

Evidence

that these sites are capable of modulating T3 delivery can
be inferred from the finding that the specific binding of
T3 at these sites is altered by changing the composition
of dietary fat (Venkatraman et al., 1986).
1.1.6

Cellular Location of the T3 Receptor
Determining the subcellular location of receptors for

a hormone with effects as diverse as those of thyroid
hormones is likely to be difficult.

Conclusive proof of

the identification of the T3 receptor requires adding
isolated T3-receptor complexes to an in vitro system and
showing that duplication of the known effects of T3 are
dependent on these T3-receptor complexes,

Candidates in

initial attempts to elucidate its site of action included
cellular components known to bind T3 and those thought to
mediate cellular effects of thyroid hormones.
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As previously stated, the effect of T3 in elevating
enzyme levels is correlated with mRNA levels.

This

suggests that one site of action might be the
transcriptional complex.

Effects on thermogenesis and

respiration suggest that another possible site might be
the mitochondrion.

Dozin et al. (1985b) used

photoaffinity labeling to label T4 binding proteins in the
plasma membrane, cytosol, and the nucleus of rat
hepatocytes.

Although they demonstrated the existence of

multiple binding sites, they could not assign any function
to these sites.
1.1.6.1

Mitochondria

Since one of the effects of T3 is to increase
respiration in the mitochondria, the mitochondrion would
be expected to have a T3 receptor,

Accordingly, the inner

mitochondrial membrane has been demonstrated to have T3
binding sites which are associated with stimulation of
mitochondrial RNA synthesis (Barsano & DeGroot, 1983).
This mitochondrial T3 receptor has a Ka 100 fold higher
than the nuclear T3 binding site and a molecular weight of
150,000.

Hashizume et al. (1986) also found binding sites

in the outer mitochondrial membrane? however, these sites
were thought to be carrier proteins functioning merely to
transfer T3 to binding sites in the inner mitochondrial
membrane.

Even though the inner mitochondrial membrane
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binding site has a high affinity for T3, this site is not
thought to be the primary initiator of the effects of
thyroid hormones.

In the absence of any known link

between the mitochondria and the production of nuclear
mRNA and with the early discovery of the nuclear binding
site, this mitochondrial receptor has been largely
ignored.
1.1.6.2

Nuclear

DeGroot and Torresani (1975) demonstrated T3 binding
to isolated nuclei? formaldehyde can cross-link a T3
binding protein to chromatin (Spindler et al., 1975).
Together these findings suggest that the T3 receptor is in
close proximity to DNA.

The receptor can also be

extracted from chromatin with 0.4 M KC1.

It now appears

to be non-randomly distributed on DNA and enriched on
actively transcribing DNA (Apriletti et al., 1983?
Gardner, 1975).

The receptor is also preferentially found

in the inter-nucleosomal spacer region.
Further evidence for receptor-chromatin interaction
is seen in the studies of Anselmet et al. (1983).

They

demonstrated a rapid decrease in T3 binding to purified
receptor preparations during storage for 24-48 hours at
0 ° C.

This loss of affinity was accelerated by the

addition of exogenous arginine-rich histones (H3 & H4),
but reversed by other histone fractions (especially HI)
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and DNA.

Addition of histones alone increased the number

of binding sites remaining over time but decreased the
apparent binding affinity.

Addition of histones with DNA

restored both the affinity and the number of receptors.
Bismuth et al. (1985) also protected the nuclear T3
receptor from degradation during isolation with histones,
DNA, and a non-histone protein.
Additional evidence that the nuclear T3 binding site
is actually the T3 receptor comes from T3 analogs which
show that relative affinities for this nuclear protein are
comparable to their biological activity.

Tissues which

are responsive to T3 also contain this protein in amounts
proportional to their response to T3 (Barsano & DeGroot,
1983).
Studies with T3 responsive genes have shown that T3
induces alterations in chromatin structure as indicated by
demethylation and increased DNase I sensitivity (Jump et
al., 1987? Nyborg & Spindler, 1986).

Later studies on the

5'-flanking region of the growth hormone gene have
demonstrated that thyroid hormones require the sequences
between -254 and -241 in order to act as an enhancer of
growth hormone transcription (Wight et al., 1987; Barlow
et al., 1986? Koenig et al., 1987).

The sequences between

-46 and -21 are required for an inhibitory effect by
thyroid hormones.

These sites suggest sequence specific
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binding by the DNA binding domain of the thyroid hormone
receptor.

However, the fact that T3 modulates the growth

hormone promoter in only a few cell types indicates that
cell specific factors are also involved (Crew & Spindler,
1986).

Also, short-lived proteins are required for almost

all the effects of T3 on RNA synthesis (Santos et al.,
1987? Jacoby et al., 1987).

By blocking protein synthesis

as little as 30 minutes before T3 addition, its ability to
increase the transcription of growth hormone RNA is
abolished.

Thus, either there are labile transcriptional

elements involved (but general RNA synthesis is not
blocked), or else the T3-receptor complex interacts with
DNA-protein complexes.
1.1.7

Physical Parameters of the T3 Receptor
The known physical parameters of T3 receptors are

summarized in Table 1.
constants observed.

Table 2 summarizes the T3 binding

Seelig et al. (1981) examined the

kinetics of T3-receptor association and dissociation,
noting a discrepancy between the half-life for
dissociation calculated from the two sets of data.

They

found that the addition of further aliquots of T3 receptor
to a previously incubated mixture of T3 receptor
containing an excess of T3 did not increase specific T3
binding.

The combination of these two factors caused them

to suggest that T3 becomes associated with nonspecific
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Table 1:
Physical parameters of thyroid hormone receptors including
sedimentation coefficient, stokes radius, molecular
weight, density, and isoelectric pH (pi).
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Table 2:
Binding constants of thyroid hormone receptors.

21

A

vo

CO

o\
iH

a)
o

c
0)
H

a)

<4-1

<D

Pi

CO
CO

in

o^
«—i

12 H
^ in *h n*

0^

«h t"''
»■

15 15
cm eg
CO
co co
CO
OV O'* VO
CO CO CO o 0^
HHcovovor^avavr^corH

a)
i—i

CO -P CO > CO CO

O^COCOCOHHO^O^
rH rH
»■ •• H O* OV 0>
• •
rH «H rH ^ '■
rH rH *>
*> ^
•• ^ rH rH • •
••CO (0 (0 •
rH • • •(dfflrHrH
• co
rH Ov -P -P IdrHrHrH
(0 fO
fd rH Q) Q)
<d (d <d -P -P

o o^ <d o^ o^

•
rH

rH O rH C/D «H
Jh
■» -H
<0 -a
• 0) • O' •
■PrHQrH P rH
(d 3 (d
CD fd
CQ
1J
P 41
41

*•

»H

rH
<d
-P
Q)

CO CO
00 CO

-H Q) 41 41 41
0) 0) 0) P P
41
rH
C
Q) Q) rH C fd
rH O O P
T50<dC-H00<D33<l)-H*Hg>i>i(d<dP
CrH W-H CnrHrH
CT> tT>*H (d (d C g C
•HrHpNp^rHgPPOPP^SSPPO
CU3(d03J333(dOO<d3J^fdQ)(])(U3P
C/DOCQQCQOUWKKPQCQCQISQQCQCQU

rH rH

a) a> -P -p
a) a) i:

-p

41

ojfDoo^fuowi:!:

<j\ cn

a) a)

rH rH

o o
&H

eh

<J
SS
Q

o tr*
PQ g

S \
rH

«H

h*

CO
•
O

r- in

eg 03

03 03

• • «H
O O

OHO

H 03

o
g

Q<
03

T3

O
o rH
03 CO ^ VO co ©
• • 03 H • •
• 03 03
CO CO CO H
H CO O
03
O

a\ n i

X
S
O
H

o

VO

^
rH

H

O

in • in H. ^.
m h oi ^ ^

o

H

H* 03
O 03

c
o
■H

-P

o

tj

3

a)

41 *H
fd T3 w a) -h
•H 0) fd rH QJ
p tp (P O H
3
P
n
3 O
H 12 0) C
S 3
pH g 41 O -H -H \ s
CD

c

41
3
0)

g

\-p
o P
a 3

>. a

Eh g
o
<D U

3

in
W
-H
EH

rH
rH
0)
O

•H
Q)
rH
U
3
S

*H
0)
rH
O -H
3 0)
S H

Q)0)*Hl30)Q)3'sv
•H
w o
(U-HUSWUHHLQQ)
0) W 3
•H *H *H *H
41 0) S
rH 0)
O O O O 41
0) 0) 0) 0)
>i4l \
pH rH rH rH ’H UH4l 3 >i4l 3 3 rH >1
0U00a)300g4l'HSS^0H0>iQ)
3333H2533W-HSWCOOOOW
Z552:55O\Z4J3C\pp3^0)^OO
w w 3 c\ch*h41 a) o) p a-H ai^ a

pppPSOHHa4Hp>>Og4lg3-H
0) 0) 0) 0)\P 3W<4H 3-H-rH
>1 p >1 0) 'O
>>>>Eh3-H H C03 (UPJH 0)15 OPlP)<
o
C
•H -H *H -H rfj 0) rH 33 33
33

G 3 C
0) 0) -H 3
PIJIDPIOQSSOOO ^
0^1/11/1030333
4141414141414141411-2 0) 3 3 P g S g g g

333333333
rtpcJ&tfptfpcJflS&G;

0)0003
CQ£aa3C

333
33K33

c

H

0)

g

>i

N

C

C
O
•H
41
3
pH
3

ip

g

O
•H
pH
3

41

X
3

x

s

in

33

o

a

3
£

eg

eg

H

H

22
sites from which it is only slowly released.

Previous

studies utilized a T3 binding resin to determine the level
of free T3.

Seelig et al. (1981) determined that the

resin removes T3 from some of the nonspecific sites giving
a false, high value for free T3.

They called these sites

"inapparent, nonspecific sites" since they had not been
recognized previously.
The presence of nonspecific sites with essentially
irreversible binding over the time span of normal binding
assays brings the assumptions for Scatchard plots into
question.

After considering the kinetics of association

and dissociation, Seelig et al. (1981) proposed a model
which could explain both the kinetic and Scatchard plot
data.

This model accounts for the normal appearance of

Scatchard plots by proposing mimicry of equilibrium
binding by a kinetic phenomenon.

Thus, as suggested in a

previous section, T3 may not be completely free, but
instead may be reversibly bound to nonspecific binding
sites.
Yagura and Walfish (1982) disagree with the
conclusion of Seelig et al. (1981) that the inapparent
sites invalidate binding assays,

They feel that

prewarming the binding assay at 30°C for 40 minutes will
allow equilibrium to be reached and by accounting for
endogenous T3, Scatchard plots will give meaningful
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results.

In an apparent concession to the widespread

usage of Scatchard plots, Seelig and Oppenheimer (1982)
have continued to report data analyzed by Scatchard plots
and have agreed that the equilibrium constant depends
markedly on temperature.
The results of binding studies have also been
questioned because they may overlook the biological
significance of 3,351-triiodothyronine (rT3) binding.
Smith and Eastman (1980) demonstrated separate binding
sites for T3 and rT3 and suggested that rT3 may have a
physiological role.

Dithiothreitol (DTT) is added to most

binding assays to maintain T3 binding due to its effects
on cysteine residues in the receptor? however, reduction
decreases the amount of rT3 binding to the point that it
is insignificant, thus rT3 binding is often overlooked.
Reduced sulfhydryls may regulate nuclear T3 and rT3
binding, but current assay methods will mask this
phenomenon.
Attempts in this study to utilize the DEAE-cellulose
filtration method of Heintz et al. (1984) were
unsuccessful.

Personal communications with this

laboratory confirmed the sensitive nature of this assay
method.

The use of G-25 Sephadex gel filtration, although

time consuming, is suitable for binding studies on large
amounts of crude receptor preparations.

However, with

24
smaller amounts of more highly purified receptor, protein
adsorption to Sephadex results in a complete loss of the
receptor protein (Latham et al., 1981).

Thus, binding

studies completed without the use of nitrocellulose
filtration (Inoue et al., 1983) had additional technical
difficulties to overcome.

The separation of receptor

bound T3 from free T3 was generally difficult to carry out
with good reproducibility.
1.1.8

Mechanism of Action of Thyroid Hormone
In light of the diverse effects of thyroid hormones,

one can see why it has been difficult to determine their
cellular site of action and their complete mechanism of
action.

Nevertheless, a number of theories have been

proposed on the basis of assumed sites of action and
supportive data have been presented for some of them.
Proof of a mechanism would involve selective blockage of
steps in the process to show that they are required for
the transduction of the effect or conversely, the addition
of components in an artificial system to recreate the
effect.

In the absence of requisite steps one relies on

temporal sequences to suggest the path of action.

The

final products may also give clues to the identity of
important steps.

Since many of the effects of thyroid

hormones result in alterations in the levels of proteins.
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a major area of focus has been investigation of the steps
involved in protein synthesis.
One mechanism whereby T3 might influence the level of
expression of a protein is to regulate the activity of RNA
polymerase.

The rate of synthesis of RNA is stimulated by

T3 and cytoplasmic RNA content is increased by 50-70% over
that of the thyroidectomized rat following T3
administration.

This would support the hypothesis that

RNA polymerase might be involved.

Increases in RNA

polymerase have also been seen in isolated nuclei
incubated with T3 (Towle, 1983).

Similarly, Nakamura et

al. (1987) reported that RNA polymerase I activity is
increased by T3 in mature rat brain.

On the other hand,

in vivo no differences in RNA polymerase activity were
seen after T3 administration by Shields and Tata (1976).
Savouret et al. (1985) found that thyroid hormone
receptors interact preferentially with the SV40
minichromosome.

Ten times more T3 receptor was associated

with the replicating viral DNA than with cellular DNA.
This suggested a preference for transcriptionally active
chromatin.

Oppenheimer (1985) agrees with this

observation and further suggests that T3-receptor binding
to chromatin might cause increased transcription.

These

speculations have been greatly bolstered by the previously
mentioned studies (Wight et al., 1987; Koenig et al..
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1987? Barlow et al., 1986) which demonstrated a
requirement for specific DNA regions 5

of the growth

hormone gene in order to have T3 stimulation of growth
hormone transcription.
Since the amount of growth hormone is increased by T3
and both have direct effects on RNA expression, their
effects need to be separated.

Up to 40% of the RNA

stimulation associated with T3 administration is directly
related to the T3 dependent increase in growth hormone.
Growth hormone and T3 effects can be separated since
growth hormone effects on RNA polymerase peak at 3 hours?
whereas, those of T3 peak at 24 hours.
Another process that could mediate T3 effects is
phosphorylation.

Changes in the phosphorylation of

nuclear proteins have been observed as a result of
administration or withdrawal of T3? however, no mechanism
has been proposed that requires phosphorylation,

Knopp

and Brtko (1984) were able to show a correlation between
phosphorylation of nuclear non-histone proteins and
changes in RNA synthesis resulting from the addition of T3
or T4.

Additionally, the phosphorous content of ribosomes

is lower in the thyroideetomized rat.

This may lead to an

altered ribosomal configuration and decreased
translational activity.
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Biro (1983) proposed a model for thyroid hormone
action in which the two aromatic rings of T3 are used to
link two macromolecules.

In this model, each of the rings

of T3 binds a macromolecule.

The amino moiety of T3 might

also be incorporated into proteins which would further
facilitate the linking of macromolecules.

However, at

high T3 concentrations every binding site would be filled
with a separate T3 molecule, thus preventing linking.
This model would then provide a simple explanation of why
the elements of oxidative phosphorylation dissociate in
thyrotoxicosis.
In addition to possible effects on macromolecular
linking, phosphorylation, or effects on transcription, T3
may have other means to assert its actions,

The plasma

membranes of cardiomyocytes appear to be a target for a
direct action of thyroid hormone.

T3 effects are also

tissue specific even though the nuclear receptors appear
to be identical.

Thus, there may be cell-specific factors

which mediate the effect of T3.

In any event, since there

appear to be multiple binding sites, there may be multiple
mechanisms leading to the final T3 dependent response.
1.1.9

Control of Thyroid Hormone Receptor Number
The nuclear receptor has a 5 hour half-life and about

95% of the receptor is replaced in 24 hours,

This

extensive renewal of receptor allows the number of binding
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sites to be easily altered by changes in the rate of
receptor synthesis.

Addition of T3 to GH-j^ cells decreases

the rate of synthesis of receptor by 60% (Samuels et al.,
1983? Raaka & Samuels, 1981? Samuels et al., 1976).
Later, it increases the rate of degradation by 30% so that
receptor half-life decreases to 3.3 hours.

In contrast,

Nakamura et al. (1979) found that T3 administration
increases the number of rat liver nuclear T3 receptors in
hypothyroid rats.

The anterior pituitary also

demonstrates an increase in the number of T3 receptors in
response to T3 (Lemarchand-Beraud et al., 1987).
Many conditions yield altered numbers of nuclear
receptors.

Burgi et al. (1986) summarized numerous

reports indicating that a decreased MBC can result from
fasting, thyroidectomy, hypophysectomy, adrenalectomy,
partial hepatectomy, glucagon treatment, T3 treatment,
cholera toxin treatment, the presence of liver tumors, and
uremia.

Overfeeding increased the hepatic MBC, while

cold-exposure and diabetes did not have an effect (Burgi &
Burgi-Saville, 1986? Las & Surks, 1981).

Again,

conflicting results have been obtained from other tissues.
Burman et al. (1980) found the T3 receptor number in human
leukocytes to increase with fasting and in hypothyroidism
in contrast to the decreases reported in rats.
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1.1.10

A Thyroid Hormone Receptor Gene

Weinberger et al. (1986) described a human c-erb-A
gene located on chromosome 17 that encodes a T3 binding
protein.

This gene has been sequenced and encodes a

polypeptide of 456 amino acids with a molecular weight of
52,000 which is thought to be the T3 receptor.

Sap et al.

(1986) have likewise isolated the c-erb-A gene from
chickens and predicted a molecular weight of 46,000 for
the gene product.

The product of this gene is thought to

be the thyroid hormone receptor because its affinity for
T3 analogs matches the known biological effects of these
analogs.

There may be several variants of the T3 receptor

since the genome contains a number of c-erb-A related
genes and the c-erb-A gene encodes two mRNAs.
Comparison of steroid hormone receptor genes and the
newly reported retinoic acid receptor gene (Giguere et
al., 1987) to the thyroid hormone receptor gene has
revealed a common structure.
domains.

The receptor genes have 5

The central domain expresses a highly conserved

metal binding "finger” region which forms the DNA binding
portion of the receptor.
X2-cys repeats.

The fingers are formed by cys-

A hinge region in the gene connects the

DNA binding region to the specific ligand binding domain.
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1.2

Triiodothyronine Resistance in Han
Thyroid hormone resistance is a state in which the

effects of thyroid hormones are not expressed due to a
failure to transduce the presence of ligand into its
normal effects.

High thyroid hormone levels exacerbate

diabetes, therefore one might expect individuals with
thyroid hormone resistance to display increased symptoms
of diabetes.

Patients with thyroid hormone resistance

display deaf mutism, delayed bone maturation, stippled
epiphyses, goiter, and high circulating thyroid hormone
levels (Refetoff et al., 1972; Bernal et al., 1978).
However, no increase in the number of patients showing
diabetic symptoms was reported in those with thyroid
hormone resistance.

In general, the patients appeared to

be euthyroid and had normal TSH levels even though T3 and
T4 were high (Refetoff, 1982).
1.3
1.3.1

Thyroid Hormones and Diabetes
The Effects of Thyroid Hormones on Diabetes
In spite of the lack of a causal relationship between

high thyroid hormone levels and diabetes in human studies,
there are a number of interactions between them.

The

effects of thyroid hormones on insulin depend on the level
of T3 and T4 present,

Malaisse et al. (1967) found

thyroid hormones to increase insulin levels in the
hypothyroid rat, but to decrease insulin levels at high T3
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levels.

Thus, thyroid hormones have a biphasic effect on

islet function.

High T3 elevates blood sugar, increases

the rate of glucose absorption, increases hepatic
gluconeogenesis, and decreases hepatic glycogen content.
With severe hyperthyroidism one sees diminished insulin
secretion.

Administration of T4 to obese mice inhibits

glucose-induced insulin secretion, as well as decreasing
overall pancreatic insulin content (Lenzen & Kloppel,
1978).
In adipocytes in cell culture, low thyroid hormone
levels are associated with greater conversion of glucose
to carbon dioxide and lipids than at normal thyroid
hormone levels (Mariash & Oppenheimer, 1983).

Yet most

studies report non-responsiveness to insulin in
hypothyroid animals.

This may be due to low growth

hormone levels since addition of growth hormone restores
responsiveness to insulin.

Administration of T3 to levels

seen in hyperthyroid rats causes them to make more ketone
bodies and less triglyceride than euthyroid rats
(Olubadewo & Heimberg, 1985).

Glycerol addition in cell

culture reduces ketone body production and increases
triglyceride synthesis suggesting that glycerol
3-phosphate acyltransferase is involved.
Tahiliani and McNeill (1985) observed that T3
treatment normalizes the depression of a cardiac myosin
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ATPase seen in the diabetic rat.

Methyl palmoxirate is a

fatty acid analog which inhibits fatty acid oxidation,
thereby forcing carbohydrate utilization and preventing
the depression of calcium uptake in sarcoplasmic reticulum
in the diabetic rat.

Triiodothyronine in combination with

methyl palmoxirate can normalize diabetic cardiac function
to the level of controls.

Triiodothyronine administration

also normalizes pulmonary lipogenic enzyme activity
otherwise decreased in streptozotocin-induced diabetic
rats.
1.3.2

The Effects of Diabetes on Thyroid Hormones
Das and Ganguly (1981) found the T3 binding capacity

in diabetic rat lung nuclei to be decreased.

Diabetes,

hypophysectomy, and thyroidectomy all lowered serum T3 and
T4 as well as the nuclear MBC (Wiersinga et al., 1982).
On the other hand, Las and Surks (1981) saw decreased
serum T3 and T4 but saw no change in hepatic nuclear T3
binding capacity or serum thyroid-stimulating hormone
(TSH) levels in diabetics.

Glucagon lowers the MBC and

could be a mechanism in diabetes which might affect the
MBC (Dillmann et al., 1978).

Glucose increases serum T3

and also the T4 to T3 conversion (Gavin et al., 1986).
Conversely, insulin and steroid hormones decrease the T4
to T3 conversion (Hidal St Kaplan, 1986) .

In contrast.

insulin is required for normal liver monodeiodinase
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activity in LA/N-cp rats (Tulp & McKee, 1986) and insulin
deficiency reduces T3 levels.

The clearance rate of T3

and T4 in the diabetic rat is also lower, but can be
normalized by insulin (Jolin & Ortiz-Caro, 1985).
It should not be surprising that the effects of
changing insulin levels in diabetes would also have
effects on products considered to be primarily regulated
by T3.

Glucocorticoids, insulin, epidermal growth factor

(EGF), and T3 are all involved in the control of growth
hormone secretion.

Glucocorticoid acts synergistically

with T3 to increase growth hormone mRNA, increasing the
number of RNA polymerase molecules synthesizing growth
hormone RNA.

Insulin inhibits the glucocorticoid response

and EGF interferes with T3 effects.

Conversely, malic

enzyme is increased by insulin and T3, while glucagon
counters the T3 effect (Roy, 1983).
Studies on the leukocytes of human diabetics have
been conducted, although it is difficult to obtain
reproducible data from leukocytes.

Kvetny (1983) found in

human mononuclear cells that the only statistically
significant difference in thyroid hormone binding
parameters was in the MBC between type I diabetics and
normals.

He saw no binding at 3°C after 18 hours, almost

the same conditions used for binding in this study.
T*i•j

The

values he observed for diabetics were slightly below
a.
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those of controls, but the differences were not
significant.
Studies examining T3 and T4 levels in diabetic
C57BL/KsJ-db m mice found total serum T3 to increase
slightly and T4 to decrease slightly at puberty, which is
also the time of onset of diabetic symptoms (Fehn, 1983).
The T3/T4 ratio was significantly altered but fasting
could normalize the ratio.

Triiodothyronine seems to

feedback on the thyroid, while T4 inhibits the pituitary
(Erfurth & Hedner, 1988? Larsen & Silva, 1983; Pascual et
al., 1987).

The thyroid gland was hypoactive in spite of

normal TSH levels.
t3.

This is probably due to the increased

Although total serum T3 is increased, there is

increased serum binding of T3 so that free T3 is normal or
only slightly elevated (Richard Fehn, personal
communication).
1.3.3

Carbohydrate, Diabetes, and Thyroid Hormone
Studies comparing the induction of malic enzyme with

the level of nuclear T3 receptor saturation suggested that
the T3 signal is highly amplified (Oppenheimer, 1978).
The biological response curve is also shifted to the left
of the nuclear receptor occupancy curve implying a
difference in stoichiometry (Samuels, 1983).

Further

investigation suggested that T3 is acting to multiply a
carbohydrate-derived signal, since carbohydrate increases
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induction of lipogenic enzymes even in the absence of T3
(Mariash & Oppenheimer, 1983).

In the diabetic rat the

response of malic enzyme to T3 is diminished, but fructose
restores T3 induction of malic enzyme,

This is

significant because fructose, unlike glucose, can be
utilized by diabetic animals,

It also is consistent with

the hypothesis that a product of carbohydrate metabolism
is interacting with the T3 signal.
Triiodothyronine levels may also be directly affected
by the composition of the diet,

Overfeeding in general

increases T3 levels in man, although T3 levels increase
only slightly in the rat (Mariash & Oppenheimer, 1983).
The conversion of T4 to T3 is also partly dependent on the
presence of carbohydrate.

In opposition to Mariash &

Oppenheimer, Yang et al. (1987) found serum T3 to not be
changed by a carbohydrate restricted diet if fat intake
was not reduced even though calories were lowered,

In two

previous studies, they reported a change in T3 with
general caloric restriction.
1.3.4

Obesity and Thyroid Hormones
Tulp and McKee (1986) examined LA/N-cp rats which

develop obesity,

They found that these animals have lower

serum T3 and resting metabolic rates than lean animals.
They also failed to show an elevation of serum T3 with
cold exposure, cafeteria feeding, and low protein diets.
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In addition, they reported that these animals were
refractory to the effects of injections of T 4' but not to
t3.

They also have less in vitro conversion of T4 to T3.

This decreased deiodinase activity was considered to be
contributory if not causative in the development of
obesity.

Similarly, Khan et al. (1986a) found a decrease

in T3 receptors in nuclei from obese mouse liver which
preceded the onset of obesity,

They proposed that the

decrease might be the primary determinant in the etiology
of this condition.
On the other hand, only 50% of the Zucker fatty rats
showed decreased T3 receptor concentrations (Khan et al.,
1986b).

Since not all Zucker rats had reduced T3 receptor

levels, additional factors may be involved in their cold
sensitivity, hypothermia, and obesity.

Hillgartner and

Ramsos (1987) examined obese mice and found the same
nuclear hepatic T3 MBC and Kd as normals.

Their results

conflicted with the results of Guernsey and Morishige
(1979), but Hillgartner and Ramsos explain the results of
Guernsey and Morishige as being an artifact of detergent
treatment of the nuclei.

Hillgartner and Ramsos did find

that the nuclear occupancy of T3 receptors was lower in
obese mice than in normals.

The obese animals had a

decreased Na+-K+-ATPase activity and cold intolerance that
was partially reversed by T3 administration.

They
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proposed that lower nuclear occupancy in spite of normal
serum T3 levels results from reduced transport of T3 from
plasma to the nucleus.

This position is consistent with a

proposed decrease in membrane fluidity in obese mice.
Decreased fluidity might be expected to affect membrane
proteins and accordingly they have shown decreased
transport of labeled T3 across the plasma membrane.
1.4

Ligand Binding
In order to understand a ligand binding phenomenon, a

model is useful as the framework on which to build that
understanding.

The simplest model is one in which one

type of ligand (L) binds to a receptor (R) having only one
binding site to form the ligand-receptor complex (LR).
L + R - LR
This model is also the most popular because of its
simplicity.

All of the biological responses resulting

from the presence of the ligand are considered to be due
to the presence of the ligand-receptor complex.

In order

to compare the tendency of various ligands and receptors
to associate or dissociate, a constant

is defined to be

Kd = [L][R]/[LR]
Another quantity called the maximum binding capacity is
useful in understanding the ligand-receptor system,

The

maximum amount of ligand that can be bound if there is
only one site per receptor is equal to the amount of
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receptor present.

Thus, in this model, the MBC is equal

to the amount of receptor present.

A third symbol often

used is v which is defined as the moles of ligand bound to
the receptor ([LR]).
To experimentally determine the binding constants,
the following scheme is often used.

Generally, the

receptor is purified to minimize interferences and
background binding.

A ligand which can be detected is

incubated with the receptor preparation to allow binding.
Separation of the free ligand from that bound to the
receptor gives the equilibrium concentration of bound and
free ligand for the receptor concentration used.

By

incubating the receptor with a range of ligand
concentrations, a curve can be constructed and the
estimated.

The amount of receptor with no ligand bound is

then MBC - v.

Substitution into the definition of Kd

yields
Kd = [L](MBC - v)/v
Since one determines the amount of bound ligand and free
ligand, this equation is frequently rearranged to
v/[L] = MBC/Kd - v/Kd
From this Scatchard (1949) pointed out that a plot of
v/[L] versus v will have a slope of -1/Kd and an X axis
intercept of MBC.

39
This type of analysis is now routine for studies on
ligand-receptor interactions.

It is not without potential

faults however, especially in the case of thyroid
hormones.

Endogenous ligand remaining bound to the

receptor after the isolation procedure must be accounted
for in order to get the true

and MBC.

A second problem

is the determination of the amount of unlabeled ligand to
add.

In almost all binding assays there is a significant

amount of binding to assay components that are not
receptors.

This "nonspecific” binding must be quantified

and subtracted from the total amount of ligand binding in
order to determine how much ligand is binding to the
receptor.

To determine the extent of nonspecific binding,

unlabeled ligand is added with the assumption that an
excess of unlabeled ligand will effectively compete
against the labeled ligand binding to the receptor and
leave only nonsaturable, nonspecific binding.

But again,

how much unlabeled ligand is the appropriate excess to
add?

Levitzki (1980) proposes that 10-fold more unlabeled

than labeled ligand determines the level of nonspecific
binding.

More commonly 100 to 1000 times the level of

labeled ligand is added.

However, large excesses of

unlabeled ligand may alter nonspecific binding, decrease
binding by noncompetitive inhibition, alter equilibrium
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conditions, or increase binding by competition with a
second component (Clark & Peck, 1979).
As binding is examined over a range of ligand
concentrations one must remember that equilibrium
conditions with saturating ligand levels are not
equilibrium conditions for subsaturating levels of ligand.
The duration of the incubation period may have to be
lengthened or the temperature may have to be increased to
achieve equilibrium.
Even after completing an assay, potential problems
remain in interpreting the data.

The common practice of

extrapolating from Scatchard plots to the X axis to
determine maximum binding capacity has been questioned by
Klotz (1982).

He suggests plotting the moles of ligand

bound versus the logarithm of the free ligand
concentration to allow a better determination of the MBC.
He further suggests that one must at least measure binding
to the inflection point of such a plot to have any
accuracy in determining the MBC.
Munson and Rodbard (1983) agree that maximum binding
capacity cannot be proven, but they disagree with Klotz
that alternative methods of plotting binding data are
helpful.

Alternative plotting schemes do not change the

data contained in them, but only how they are presented.
Instead, they recommend determining the shape of the error
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range for the plot type chosen in order to understand the
extent of error in any extrapolations made.

They further

recommend the use of nonlinear least squares fitting
weighted according to the error distribution (Munson &
Rodbard, 1980).
In a later paper, Munson (1984) suggests that linear
regression of Scatchard plots is only useful for rough
estimates of binding parameters.

One should not regard

nonspecific binding as fixed, but instead treat it as
another parameter to be determined by fitting the data to
the appropriate model.

To accurately determine bound

radioactive ligand, one needs to know label specific
activity, tracer purity, counting efficiency, counter
background, and the efficiency in separating bound and
free ligand (Bonifacino & Paladini, 1981).
In the case of thyroid hormones, the intrinsic
stickiness of T3 caused researchers to examine how to
apply the concept of free ligand.

The question of

availability of T3 for interaction with the nuclear
thyroid hormone receptor was examined by Seelig et al.
(1981).

As previously summarized, addition of excess

receptor to a previously incubated mix of labeled T3 and
receptor did not cause the transfer of any T3 from the
nonspecific sites to the newly added receptor.

This

indicates that the nonspecifically-bound T3 is not
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available to participate in maintaining a binding
equilibrium, since it did not transfer to the higher
affinity receptor.

They referred to the nature of this

binding as "inapparent sites”, which although most workers
considered as reversibly bound to T3, the T3 was not
available to interact with the receptor.

If the measured

binding does not reflect equilibrium conditions, Scatchard
plots must be used with caution.
Yagura and Walfish (1982) disagree with Seelig et al.
(1981) in that they could remove 90% of added T3 by
dialysis after incubation with a nuclear extract.

Thus,

according to Yagura the "inapparent sites” do not exist or
are weak enough to allow a substantial amount of T3 to be
released and cross the dialysis barrier.

Hillgartner and

Romsos (1987) also refute the proposal of Seelig et al.
(1981) in that their experiments showed resin adsorbable
T3 to be only 10% of the total T3 after in vivo injection
and isolation of nuclear extract.
Finally, Levitzki (1984) points out that not every
high affinity site is a receptor,

One must demonstrate

ligand displaceability, saturability, and binding must
correlate with a biochemical activity.

The biological

effectiveness of hormone analogs will depend on the amount
that binds the receptor, the intrinsic efficacy in
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eliciting a response, and the duration of binding to the
sites.
1.5

The C57BL/KsJ-djb m Mouse
In 1966, Hummel et al. described a spontaneous

mutation which developed in C57BL/KsJ mice.

Mice were

studied which experienced an unusual increase in weight.
These animals were found to have high blood sugar (200
mg/100 ml serum) and thus by definition are diabetic.
Coleman and Hummel (1967) in defining this mutation found
that it was transmitted on chromosome 4 as a unit
autosomal recessive gene with full penetrance.

Autosomal

recessive mutations generally are the result of a single
nucleic acid base change, which if true in this case,
would mean that a change in a single gene product should
explain all the alterations in this diabetic state.
Diabetic animals are infertile, while heterozygotes can be
distinguished from normals only by their offspring.

Chick

et al. (1970) disagreed that heterozygotes are the same as
normals because they observed slight increases in blood
glucose in males.

Three stages are discernable in the

development of the diabetic state (Basabe et al., 1983).
In the period after birth from 10 to 30 days there is
hyperinsulinemia and hyperglucagonemia.

At 4 to 12 weeks

of age, hyperglycemia and obesity develop.

From 12 to 24

weeks, insulin resistance and (3 cell necrosis emerge with
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premature death at 24-32 weeks.

The diabetic defect may

be due to the hypersecretion of glucagon leading to high
hepatic glucose output with increased beta cell
stimulation, thereby giving rise to high insulin levels
and later insulin resistance until there is islet
exhaustion (Bray & York, 1979).

Increased lipogenesis

leads to hypertriacylglycerolemia explaining the weight
gain of diabetic animals.

Diabetic animals also lack the

T3 induction of the Na+-K+-ATPase which would make them
tend towards obesity and suggests thyroid hormone
resistance.
Wyse and Dulin in 1970 reported that limiting food
intake could stabilize blood sugar and insulin, although
these parameters are still elevated relative to normals.
In young animals, elevated insulin and increased glucose
oxidation by adipose tissue maintain the glucose
concentration at normal levels.

With increasing age,

elevated food intake, depressed glucose utilization, and
continuous output of glucose by the liver, the pancreatic
beta cells become exhausted.
The ability to produce colonies of this diabetic
strain of mice has been enhanced by the inclusion, via
crossbreeding, of a misty coat gene (C57BL/KsJ—db m) which
excludes the diabetic gene due to repulsion (Chick & Like,
1970) .

Thus, with the development of fur, the animals
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which did not receive the diabetic gene from their
heterozygous parents could be easily distinguished by
their dark gray coat from the black coated heterozygotes
and diabetics.

Offspring with black coats would either be

valuable as breeding pairs if heterozygous, or would
develop symptoms of diabetes upon maturation.

Misty coat

animals which do not carry the diabetic gene can be
discarded without having invested any significant effort
in rearing them.
1.6

Objectives of This Study
Since the diabetic mouse had indications of altered

serum T3 and T4, yet the kinetics parameters of the 5 i _
monodeiodinase were not altered (Richard Fehn, personal
communication), we proposed to study the T3 binding and
physical characteristics of the hepatic nuclear thyroid
hormone receptor in these mice,

Thus, we hoped to better

understand why the differences in T3 and T4 levels between
diabetic and heterozygous animals exist, to search for the
gene whose alteration leads to the diabetic syndrome, and
to further elucidate factors influencing the course of
their diabetes.

2. Materials and Methods
2.1

Animals for the Study
A colony of C57BL/KsJ mice was developed by breeding

sibling animals obtained from Jackson Laboratory (Bar
Harbor, Maine).

The mice were maintained on a diet of

Purina rodent laboratory chow 5001 (Purina Mills, Inc.,
St. Louis, MO) and water ad libitum at 22 ± 1°C with light
from 6 am to 6 pm in addition to partial window lighting.
Livers from C57BL/KsJ-db m mice heterozygous (db+/+m) and
homozygous (db+/+db) for the diabetic mutation were
generously supplied by Dr. Richard Fehn, Department of
Biology, California State University, San Bernardino, CA.
The diabetic and heterozygous mice were maintained on a
diet of Purina rodent chow and water ad libitum at 23°C
with light from 6 am to 8 pm.

One of the four sets used

in the binding studies was fasted 24 hours prior to
termination; however, no significant differences were seen
in their Kd or MBC compared to nonfasting animals.
Diabetics were distinguished from heterozygotes by the
fact that diabetics become fat while heterozygotes remain
lean.

Offspring homozygous for the misty coat color gene

(+jn/+;n) were discarded on the basis of their coat color
(dark gray), since diabetics and heterozygotes are black.
To control for circadian rhythms, the animals were
killed between 8 am and 10 am.
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One set of livers was
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frozen on a -80°C metal plate, but more generally livers
were frozen in liquid nitrogen.

Once frozen, livers were

kept at -70°C until used in the isolation of thyroid
hormone receptor.
2.2

Buffers
All buffers were made in ultra-filtered deionized

water (resistance >15 megohms-cm, Sybron/Barnstead
Nanopure, Boston, MA).

Unless specified otherwise, all

chemicals are reagent grade.
Buffer 1 contained 0.25 M sucrose (Schwarz/Mann Ultra
Pure, Cambridge, MA), 2 mM MgCl2, and 20 mM Tris/HCl
(Schwarz/Mann Ultra Pure, Cambridge, MA), pH 7.6 at 4°C.
Buffer 2 contained 50 mM NaCl, 10% (v/v) glycerol, 2
mM ethylenediaminetetraacetic acid (EDTA), 5 mM
2-mercaptoethanol, and 20 mM Tris/HCl, pH 7.6 at 4°C.

The

pH titration of buffer 2 was difficult because the
available calomel combination electrodes gave unstable
readings and available silver chloride combination
electrodes would be damaged by the mercaptoethanol.
Buffer 2 was therefore adjusted to approximately pH 7.6 as
determined by colorpHast pH indicator strips for pH 6.510.0 (EM Science, Cherry Hill, NJ).

Since the batch to

batch variation was significant in its effect on receptor
binding, all diabetic/non-diabetic comparisons were done
in paired assays utilizing the same batch of buffer.
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Buffer 3 contained 0.4 M KC1, 1.1 mM MgCl2, and 20 mM
Tris/HCl, pH 7.9 at 4°C.
2.3

Hepatic Thyroid Hormone Nuclear Receptor Isolation
Unless noted otherwise, all pellet resuspensions were

in 10 ml of buffer per gram of original wet liver.
Following the procedure of Inoue et al. (1983), the
nuclear T3 receptor was dissociated from chromatin and
solubilized.

Normal C57BL/KsJ mice were killed by

cervical dislocation (Cervical Dislocators Inc., Wausau,
WI) at 10-80 weeks of age.

Livers were immediately

surgically removed from the animals and frozen in liquid
nitrogen.

Diabetic animals 10-15 weeks old were used and

heterozygotes ranged in age from 10 to 22 weeks old.
However, most of the animals in all groups were
approximately 11 weeks old.

Altered T3 binding with age

was only suspected in the diabetic mice.
As needed, livers were thawed in buffer 1 at 4°C.

A

minimum of 3 livers were minced with scissors and
homogenized on ice in 60 ml of buffer 1 with 12 strokes of
a glass-teflon homogenizer (Thomas C24915, Philadelphia,
PA) driven at 1200 rpm.

The homogenate was filtered

through 4 layers of cheese cloth and centrifuged at 1,500
x g for 12 minutes at 4°C (DuPont Sorvall RC-5B
Refrigerated Superspeed Centrifuge, SS-34 rotor, Newtown,
CT) .

The supernatant was discarded and the pellet was
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Figure 1:
Flowchart of the isolation procedure for the nuclear T3
receptor, Bold numbers are the step numbers referred to
in the text.
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Kill by cervical dislocation
Surgically remove liver
Freeze liver in liquid nitrogen
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Centrifuge 12 min., 1,500 x g
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Decant & Discard Supernatant
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resuspended in the homogenizer with 3 strokes in buffer 1.
This suspension was centrifuged 10 minutes at 3,000 x g
and the supernatant discarded.

The pellet was resuspended

with vortexing in buffer 1 which had 0.5% Triton X-100
added.

After centrifugation for 10 minutes at 3,000 x g,

the supernatant was discarded and the pellet was again
resuspended in buffer 1 containing 0.5% (v/v) Triton
X-100.

The suspension was then centrifuged 10 minutes at

3,000 x g.

The supernatant was discarded and the pellet

was resuspended in buffer 2.

After centrifugation for 10

minutes at 3,000 x g, the supernatant was discarded and
the pellet resuspended by stirring for 30 minutes at 4°C
in 1 ml of buffer 3 per g liver.

This served to remove

the receptor from the chromatin and solubilized it.

After

removal of the stir bar, centrifugation at 35,000 x g for
20 minutes yielded a pellet containing the DNA which was
later assayed to determine the DNA content of the pooled
liver tissue.
The supernatant was dialyzed at 4°C against buffer 2
in Spectrapor membrane tubing overnight (cut off molecular
weight 3500, Spectrum Medical Industries, Inc., Los
Angeles, CA).

Following dialysis, the solution was

clarified by centrifugation at 3,000 x g for 10 minutes.
The pellet was discarded and the supernatant was used as
the receptor preparation.
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2•4

DNA Assay
Total liver DNA was measured by the method of

Patterson (1979) which utilizes a diphenylamine color
reaction.

The pellet containing DNA from the 35,000 x g

centrifugation in the receptor isolation procedure (Figure
1, step 2) was suspended in 2 ml of 0.5 M perchloric acid
and heated in a water bath at 90°C for 15 minutes, then
centrifuged at 3,000 x g for 10 minutes.

The supernatant

was saved and the pellet washed with 2 ml of 0.5 M
perchloric acid and the centrifugation repeated.

This

supernatant was combined with the previous supernatant and
the total volume brought to 10 ml with 0.5 M perchloric
acid.

A 10 fxl aliquot was diluted to 1 ml with 0.5 M

perchloric acid.

A diphenylamine working solution

containing 0.75 g diphenylamine dissolved in a mixture of
50 ml of glacial acetic acid and 0.75 ml of concentrated
sulfuric acid was prepared just prior to use.

An

acetaldehyde solution containing 0.5 ml of acetaldehyde in
24.5 ml of water was stored at 4°C.

Two ml of Burton's

reagent (Burton, 1956) consisting of 0.1 ml of
acetaldehyde solution and 20 ml of diphenylamine solution
was added to the 1 ml of diluted sample,

The mixture was

incubated 16-20 hours at room temperature and the
absorbance determined at 600 nm with a Beckman DB-GT
spectrophotometer (Fullerton, CA).

The absorbance was
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converted to mg DNA using a linear standard curve derived
from stock solutions of calf thymus DNA (0 to 0.04 mg
DNA/ml) dissolved in 5 mM NaOH.
2.5

Protein Assay
The Pierce Chemical Company BCA protein assay kit

(Rockford, IL) was used to determine protein
concentration.

This assay is based on the ability of

protein to form Cu+1 ions from Cu+2 ions in alkaline
solutions.

When in the presence of bicinchoninic acid

(BCA, Figure 2) , the Cu"1-1 ion interacts with two BCA
molecules to form a BCA-Cu+1 complex which absorbs
strongly at 562 nm.
Fifty ml of reagent A (BCA in a buffered basic
aqueous solution) was combined with 1 ml of reagent B (4%
aqueous copper sulfate solution) to form the working
reagent.

Fifty pJ. of the receptor preparation was diluted

with 350 jxl buffer 2.

Bovine serum albumin was prepared

as a standard (0 to 0.25 mg/ml) in buffer 2.

A 0.15 ml

aliquot of the sample was combined with 3 ml of working
reagent and incubated at 60°C in a temperature-regulated
water bath (Precision Scientific Company, No. 66648,
Chicago, IL) for 30 minutes,

Samples were cooled to room

temperature in about 30 minutes and the absorbance was
determined at 562 nm.
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Figure 2:
The structure of bicinchoninic acid (BCA) and its usage in
assaying protein concentration.
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2.6

,.125 I]T3-Receptor Binding Assay on Nitrocellulose
Receptor binding of T3 was measured by the method of

Inoue et al. (1983).

A 0.1 ml aliquot of the receptor

preparation was combined with 0.01-0.1 pmoles [ 125 I]T3 in
buffer 2 to a total volume of 0.5 ml in 12x75 mm
borosilicate glass tubes (VWR Scientific Inc., San
Francisco, CA).

Nonspecific binding was determined by

including 500-fold more unlabeled than labeled T3.

The

tubes were covered with parafilm (American Can Co.,
Greenwich, CT) and incubated for 18-25 hours at 4°C.
Nitrocellulose membrane disks (Schleicher & Schuell 25 mm,
0.45 micron, Keene, NH) were placed on a Millipore glass
fritted filtration apparatus (Bedford, MA).

All of the

solutions were held at 4°C but for convenience, the
filtration apparatus was not cooled except by the cold
solutions as they passed through it.

The membranes were

moistened by aspiration with 3.5 ml of buffer 2.

The

samples were diluted with 3.5 ml of buffer 2 and filtered
through the nitrocellulose at 12 ml/minute,

Each

incubation tube was rinsed by vortexing with 3.5 ml of
buffer 2 which was then used to rinse the filtration
apparatus including the nitrocellulose membrane.

A second

3.5 ml aliquot of buffer 2 was used to rinse the
incubation tube, filtration apparatus, and the
nitrocellulose membrane.

The membrane was washed twice
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more with 7 ml of buffer 2, then membrane-bound 125 I was
determined by counting the membrane for one minute in
polypropylene tubes using a Nuclear Chicago gamma counter
(model 1185, Des Plaines, IL).

Counting efficiency was

85.3 ± 0.1%.
2.7

Determination of 125i~ in Stock [125I]T3 Solutions
Iodide was separated from T3 by the method of Green

(1972) .

A 1 x 5 cm G-25 superfine Sephadex column

(Pharmacia Fine Chemicals Inc., Piscataway, NJ) was
equilibrated with 0.015 M NaOH, 0.5 M NaCl at room
temperature.

Ten |xl of the [ 125 I]T3 solution to be

assayed was added and 1 ml fractions collected,

The

column was washed with 5 ml of 0.015 M NaOH, 0.5 M NaCl to
elute the iodide peak near the total column volume.

Under

these conditions T3 is weakly adsorbed to Sephadex partly
due to interaction between the hydroxy-ether groups in
Sephadex and the hydroxyl on the terminal aromatic ring of
t3.

At low ionic strength, the carboxyl groups of

Sephadex act as a weak cation exchanger to bind T3.
Elution can then be effected by increasing the pH which
diminishes the interaction between Sephadex and T3.
Elution of T3 and T4 was accomplished by washing with
10 ml of 0.1 M NaOH, 0.005 M NaCl.

The fractions were

counted to quantify 125I, and the 125i“ to [ 125 I]T3 ratio
in the stock solution was determined by comparing the

58
areas under the peaks.

This ratio then allowed the

calculation of the percent of the radioactivity that is
due to [ 125 I]T3.
2.8

Calculating the Amount of [125I]T3 in Stock Solutions
The use of low specific activity ligands labeled with

short half-life nuclides requires a correction in the
calculation of the amount of labeled ligand present which
is rarely addressed in the literature.

Bolger and

Jorgensen (1980) in an appendix to their paper have dealt
with this problem.

Radioactive decay follows the equation

Nt = N0e -kt
where t is time, Nt is the amount of radionuclide at time
t, Nq is the amount of radionuclide at time zero, and k is
the decay rate constant equal to the natural logarithm of
2 divided by the nuclide decay half-life,

If the ligand

is labeled with only one radioactive nuclide per ligand
molecule, the total number of disintegrations will equal
the loss of labeled ligand molecules.
Since only the radiolabeled ligand decays, the
specific activity changes with time and the calibration
constant for converting counts to moles of ligand changes.
In order to correct for the loss of labeled ligand one
must know the amount of both radiolabeled ligand and
unlabeled ligand,

The amount of labeled ligand can be

determined from the theoretical maximum specific activity
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if all the ligand was labeled.

This maximum specific

activity is determined by the nuclide half-life.

Since

with decay the amount of nuclide remaining to decay
decreases, the calculated maximum specific activity will
also decrease as the time period over which it is
calculated is increased.

As an example, at the end of one

half-life, 1/2 of the original nuclide will have decayed
over that time period? similarly, calculated over 2
half-lives 3/4 of the original nuclide will have decayed,
but since there has been twice the amount of time, the
activity per time period drops from 1/2 to 3/8.
The decay from one mole of 125i over the first one
second time interval is Nq -

or

6.022 x 1023(l-e-ln2/5,184,000) for 125i which has a
half-life of 60 days (5,184,000 seconds),

Expressed in

microcuries (jxCi) per jxg of [125I]T3 this equals 3353
fxCi/jjig.

Dividing the total jxCi of [ 125 I]T3 present by

3353 would then give the micrograms of labeled T3 present.
Dividing the total jxCi of [125I]T3 present by the specific
activity would give the total micrograms of T3 present.
From the amounts of total T3 and labeled T3 one can
calculate the unlabeled T3 present by taking the
difference (total-labeled = unlabeled).

When utilized at

a date after the calibration date, only the labeled ligand
will have been destroyed by the recoil energy of decay.
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From the decay equation, the amount of remaining labeled
ligand can be calculated.

The current specific activity

(jxCi/jxg) can then be calculated by dividing the total
activity present (jxCi) by the sum of the unlabeled ligand
and the remaining labeled ligand (jxg) .

Total activity

divided by the current specific activity gives the total
amount of T3 present:

Total activity (jjiCi)/current

specific activity (fjLCi/jxg) = T3 (jxg) .

Converting the

counts per minute (cpm) to activity present (cpm/counting
efficiency (cpm/dps) x 3.7 x 1010dps/Ci) = activity (Ci))
and using the current specific activity allows one to
convert the cpm observed to the amount of T3 present.
2.9

Association/Dissociation Kinetics
A number of 0.1 ml aliquots of the receptor

preparation were incubated at 4°C in 1-6 pM [ 125 I]T3 in
borosilicate glass tubes.

The total volume was adjusted

to 0.5 ml by the addition of buffer 2.

Four hours after

initiating the incubation, 18 jxl of 18 jxM unlabeled T3
dissolved in 0.02 M NaOH was added to 9 tubes.

Unlabeled

T3 was added to another set of 9 tubes at 24 hours and to
a third set of 9 tubes at 48 hours.

The loss of bound,

labeled T3 with time was followed utilizing the
nitrocellulose assay.

Reassociation of the labeled ligand

and receptor is prevented by the excess unlabeled ligand
present.

As shown by Seelig et al. (1981), a bimolecular.
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reversible association between T3 and its receptor has a
rate equation of
d(T3R)/dt = k+1[T0 - T3R][R] - k.1[T3R]
where T0 is the total T3 added, k+1 is the association
rate constant, and k^ is the dissociation rate constant.
Assuming T3 is in the tracer range, the concentration of
unbound receptor will not change significantly and R = Rq.
Since the integral of dX/(A + BX) is 1/B x ln|A + BX|,
integration of the rate equation yields
1
ln|k+1T0[R0] - T3R(k+1[R0] + k^) | -(k+1[R0] + k^)
1
ln|k+1T0[R0]| = t - 0
”(k+![R0] + k-i)

After rearranging
t3r

k+ltR0^

[1 - e”(k+l[Ro] + ^--1^]

k+i[Ro^ + ^-1
The maximum amount of T3 will be bound when t is infinite.
T0

Thus, the maximum T3R/Tq (ymax ) is
k+1[R0]/(k+1[R0] + k-:L)
If the percent of T3 bound to receptor is y, and X is
k+i[R0] + k_^, then the equation above simplifies to
ymax - y

ymax e~xt

The time required for half of the maximum amount of ligand
that will eventually bind to the receptor to become bound
to the receptor can be calculated from the binding versus
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time curve assuming that the amount of dissociation of
ligand from the receptor is negligible in the time
required for association.

A plot of the natural logarithm

of (the maximum percent of added ligand bound at any time
minus the current percent of added ligand bound) versus
time will give a linear plot:
ln(ymax - y) = -\t + In (ymax )
with X = -slope.

By substituting 0.5 x ymax for y, one

can see that the time for half maximal association
(Tj asso ) is ln(0.5)/-X.

The value of

can be

calculated from the definition of X and ymax to be X(1—
^max ) • The expected dissociation half-life is Tid^ss =
ln(0.5)/-k_1.

The value of k +1 is (—X - k^J/RQ, where Rq

is the MBC estimated from a Scatchard plot.

The predicted

Kd is then k^/k+T.
When looking only at the T3-receptor dissociation,
the rate equation becomes:
d(T3R)/dt = k-;L[T3R]
Integration yields:
(l/k^) x ln|k_1[T3R]| - (l/k_1) x ln|k_1[T3R0] | = t - 0
where [T3Rq] is the level of T3-receptor complex when the
excess cold T3 is added to begin the examination of
dissociation only.

Rearranging gives:

[T3R] = ([T3R0]/k_1)e-k-lt
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A plot of the natural logarithm of the percent of the
added ligand remaining bound versus time yields a linear
plot of the dissociation of the bound, radiolabeled
ligand:
ln(T3R/T0) = -k^t + ln(T3R0/k_:LT0)
The observed half-life for the dissociation of the T3receptor complex is ln(0.5)/slope.
2.10 Scatchard Binding Analysis
A 0.1 ml aliquot of the receptor preparation was
incubated overnight at 4°C in 10 -11 to 10 -8 M [ 125 I]T3 in
buffer 2 in a total volume of 0.5 ml.

Nonspecific binding

was quantified in the presence of a 500 fold excess of
unlabeled T3 over labeled T3.

The bound [125I]T3 was

determined using the nitrocellulose assay.

As described

by Scatchard (1949), a simple model for ligand-receptor
interaction can be linearized by plotting bound
ligand/[free ligand] versus bound ligand,

This can be

seen from the equation
v/[L] = MBC/Kd - v/Kd
where v is the concentration of bound ligand, [L] is the
concentration of free ligand, MBC is the maximum binding
capacity, and Kd is the dissociation constant,

Scatchard

plots of moles of bound T3 per mg protein/[free T3] (Y
axis) versus moles of bound T3 per mg protein (X axis)
were constructed.

Linear regression of the transformed
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data gave the

(-1/slope) and maximum binding capacity

(X axis intercept).
2.11 Isokinetic Sucrose Gradient Sedimentation Velocity
A 0.1 ml aliquot of the receptor preparation was
incubated overnight at 4°C in 1 nM [125I]T3.

The free

ligand was separated from protein bound ligand by gel
filtration with a 0.6 x 7 cm G-25 coarse Sephadex column
(Pharmacia Fine Chemicals, Piscataway, NJ) at room
temperature.

The column was equilibrated with 20 mM

Tris/HCl, pH 7.6 at 22°C, 20 mM NaCl, 0.1% (v/v) Triton X100, then the incubated sample was added and the void
volume collected.

The void volume was predetermined by

the elution of blue dextran 2000 (Pharmacia Fine Chemicals
Inc., Piscataway, NJ).

The column was washed between

samples with 0.1 M NaOH, 0.005 M NaCl to remove residual
free T3.

The void volume fraction was concentrated

approximately 50% by evaporation under a dry nitrogen
stream.

This void volume concentrate was layered on an

isokinetic sucrose gradient in polyallomer tubes for a
Beckman SW60 rotor (Palo Alto, CA).
To form isokinetic gradients, the concentration in
the mixing chamber (Cm) was 5% sucrose in 10 mM KC1, 10 mM
Tris/HCl, pH 7.4 at 22°C, 1 mM EDTA, 20 Units Trasylol/ml.
The concentration in the reservoir (Cr) was 24.1% sucrose
in the same buffer.

The volume of fluid in the mixing
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chamber (Vm) was held at 4.86 ml while the gradient was
formed and the initial volume in the reservoir (Vr) was 5
ml (McCarty et al., 1974; Perlman et al., 1982).
Centrifuge tubes were filled to within 0.5 cm of the top.
Samples were centrifuged at 300,000 x g (54,000 rpm in an
SW60 rotor) for 20 hours at 2°C in a L2-75B
ultracentrifuge (Beckman, Palo Alto, CA).

The centrifuge

was allowed to coast to a stop without braking.
The tubes were fractionated with an ISCO 182 gradient
fractionator (Lincoln, NE) removing the solution from the
bottom for radioactivity determinations.

Two drop

fractions were collected and counted in a gamma counter
for 125I.

For the protein sedimentation standard (2 0 jxl

of 5 mg ovalbumin/ml) the solution was removed from the
top of the tube through a quartz windowed flow cell
following the absorbance at 280 nm (ISCO UA-4 absorbance
monitor, dual beam optical unit type 4, Lincoln, NE).

The

distance sedimented in isokinetic gradients is
proportional to the sedimentation coefficient so that the
ratio of the distance traveled is also the ratio of the
sedimentation coefficients between the standard and
sample.
2.12 Immobiline Isoelectric Focusing Gels
A 0.1 ml aliquot of the receptor preparation was
incubated overnight at 4 ° C in 1 nM [ 125 I]T3. The free
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ligand was separated from protein bound ligand by gel
filtration with a 0.6 x 7 cm G-25 coarse Sephadex column.
The T3-receptor complex was eluted in the void volume.
The column was equilibrated with and the protein bound T3
eluted with 20 mM Tris/HCl, pH 7.6 at 22°C, 20 mM NaCl,
0.1% (v/v) Triton X-100.

Washing the column between runs

with 0.1 M NaOH, 0.005 M NaCl removed free T3 which was
discarded.

The void volume fraction was concentrated by

evaporation under a dry nitrogen stream.

Ten fjil of

glycerol was added to the void volume concentrate.
Aqueous stock solutions of 10% ammonium persulfate
and 10% N,N,N',N'-tetramethylethylenediamine (TEMED) were
prepared just prior to use.

The acrylamide-bis stock

solution contained 2.91 g acrylamide and 0.09 g N,N i _
methylene-bis-acrylamide (bis) in water to a total volume
of 10 ml.

The pH of the acidic (dense) gel solution was

taken when it consisted of 207.5 jjlI of pK 6.2 immobiline,
163.2 jjiI of pK 3.6 immobiline, and 1.7 ml of water.

Then

692 fjul of acrylamide-bis stock solution, 1.01 ml glycerol,
and 372 fxl of water were added.

The pH of the basic

(light) gel solution was taken when it consisted of 207.5
jxl of pK 6.2 immobiline, 44.3 jjlI of pK 3.6 immobiline, and
1.82 ml of water.

Then 692 p,l of acrylamide-bis stock

solution and 1.38 ml of water were added.

The acidic gel

solution was placed into the mixing chamber of a linear

67
gradient maker while the basic gel solution was placed in
the other chamber.

Addition of 11.1 jxl of 10% ammonium

persulfate and 18 jxl of 10% TEMED to each chamber
initiated polymerization.

Using the gradient maker, a co-

1inear density and pH gradient was formed in a 12 ml
syringe inserted into the gel apparatus (0.35 mm x 14 cm x
16 cm).

Once the gradient was formed, the syringe plunger

was used to quickly expel the gel solution into the gel
apparatus.

A 20 gauge needle was used instead of the 30

gauge needle suggested by the gel apparatus manufacturer
since the 30 gauge needle clogged too quickly,

Initially

the gel apparatus was tipped on its side so that the gel
solution would run down the side to avoid trapping air
bubbles.

As the gel solution was poured into the

apparatus, it was gradually leveled.

Heating for one hour

at 50°C completed polymerization of the gel.

The sample

wells were washed with water, then filled with anolyte
(0.02 M NaOH).

The catholyte was 0.02 M acetic acid.

The void volume concentrate was loaded onto the gel
and run at 20 watts constant power for 3 hours in a Hoefer
600 vertical slab gel apparatus (San Francisco, CA)
connected to a Bio-Rad 3000/300 power supply (Richmond,
CA).

The voltage was limited to a maximum of 2500 V.

apparatus was cooled to 4°C with a refrigerated water
recirculator (Lauda K-2/R, Brinkmann Instruments, West

The
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Germany).

After electrophoresis, the lanes were cut out

and each lane was sliced into 2 mm sections.

The sections

were counted for 125 I in a gamma counter.
2.13 Estimation of Free [125I]T3 by Binding to Subsequent
Receptor Additions
A 0.1 ml aliquot of the receptor preparation was
combined with 0.13 pmoles [ 125 I]T3 in buffer 2 to a total
volume of 0.5 ml in 12x75 mm borosilicate glass tubes.
Nonspecific binding was determined by including 380 pmoles
unlabeled T3 in an otherwise matched set of tubes,

The

tubes were covered with parafilm and incubated at 4°C.
After incubating for 24 hours, a second aliquot of 0.1 ml
of the receptor preparation was added to half of the total
and nonspecific binding tubes.

The incubation was then

continued for all tubes at 4°C for another 24 hours.

The

amount of [ 125 I]T3 bound was determined by nitrocellulose
filtration as described previously in section 2.6 on the
[

125 I]T3-receptor binding assay,

The amount of free T3

after 24 hours of incubation was calculated from the
increase in specific T3 binding when the second aliquot of
receptor preparation was present, assuming that the
equation
v/[L] = MBC/Kd - v/Kd

describes the proper model for T3 binding.
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2.14 Molecular Weight Determination by 6-100 Sephadex
The molecular weight of the nuclear T3 receptor was
estimated by G-100 Sephadex chromatography (Pharmacia Fine
Chemical, Piscataway, NJ).

The gel was hydrated in and

equilibrated to 20 mM Tris/HCl, pH 7.6 at 22°C, 20 mM
NaCl, 0.1% (v/v) Triton X-100 in a boiling water bath for
5 hours.

After cooling to room temperature, the gel was
Molecular weight

poured into a 13.2 x 0.7 cm column,

standards of aldolase (158,000), chymotrypsin A (25,000),
and ovalbumin (43,000) were prepared at 5 mg/ml in the
same buffer.

The column was run at room temperature

monitoring the absorbance at 280 nm to detect the elution
of the protein standards,

Plotting the logarithm of the

molecular weight against the fraction number for the half
maximum absorbance on the peak front yielded the
calibration curve.
A 0.1 ml aliquot of the receptor preparation was
incubated in 2.6 nM [ 125 I]T3 at room temperature for 4
hours.

The incubated preparation was then run on the

column and eluted with 20 mM Tris/HCl, pH 7.6 at 22°C, 20
mM NaCl, 0.1% (v/v) Triton X-100.

Fractions were

collected and the 125i content determined to assess the
location of the T3-receptor complex.

The molecular weight

was determined by comparing the fraction number with the
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half maximum counts per minute (cpm) in the peak front to
the standard curve.
2.15 Statistical Methods
The slopes in the Scatchard plots for control and
diabetic T3-receptor binding were compared by a one-tailed
t-test (Student, 1908) and by the method of Dixon and
Massey (1969).

See the Appendix for an explanation of the

Dixon and Massey method.
For dissociation kinetics. Student's one tailed
t-test was used to determine the probability that the
dissociation half-life was greater in controls than in the
diabetics.

Since the dissociation rate should be the same

in all replicates irregardless of the initial level of
binding, a composite slope was determined for each group,
control and diabetic, by forcing all the lines to have a
common slope in a linear least squares fit.

If one has j

lines with n^ points in line i and with k specifying the
points in line i where i is the line number (1 to j), the
slope (m) for all the lines as a group is:
j

ni
2 X ik Yik i=l k=l

2

j

2

21 X, 2

i=l k=l

ik

j
ni
ni
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2 Y
2
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k=l Xik}
K
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.
*!

71

With intercepts (b^) at
ni
ni
2 Y ik- ™ 2 X
k=l
k=l ik
ni
See the Appendix for the derivation of these equations and
a sample calculation.
All experimental values given are the sample mean
plus or minus the 95% confidence limits (C.L.).

The 95%

confidence limits are calculated as the critical
t-statistic times the standard deviation of the mean.

For

calculated values, the 95% confidence limit is estimated
by propagation of error as by Peters et al. (1974).
the Appendix for a brief explanation of this method.

See

3. Results
3.1

Isolation of the Hepatic Nuclear T3 Receptor
The protein concentration in the nuclear T3 receptor

preparation (Figure 1, step 3) was 1.1 ± 0.3 mg/ml (n=10,
mean ± 95% C.L.) for controls and 1.5 ± 0.4 mg/ml (n=7)
for diabetics.

The DNA content determined from the pellet

in step 2 of Figure 1 was 1.4 ± 0.7 mg/g liver (n=8) for
the controls and 1.5 ± 2.1 mg/g liver (n=3) for the
diabetics.

There was no significant difference between

diabetic and control parameters for either measurement.
There were significant differences (pcO.OOl) in the
weights of the two liver types however.

Control livers

averaged 1.3 ± 0.2 g (n=32), while diabetics have larger
livers averaging 2.5 ± 0.7 g (n=19).

Thus, the average

DNA per liver is higher in diabetics, 3.8 ± 5.4 mg/liver
versus 1.8 ± 1.0 mg/liver for controls.

However, the

large spread in the distribution of the DNA values
prevents this difference from being statistically
significant at the 95% confidence level.
3.2

Separation of Iodide and T3
Figure 3 illustrates the separation of iodide from T3

by G—25 Sephadex chromatography.

Commercial stock

(-125 I]T3 solutions generally contain less than 2% iodide
upon arrival.

Spontaneous deiodination of T3 increases
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Figure 3:
Separation of iodide from T3 in commercial stock [125 I]T3
solutions by G-25 Sephadex chromatography, The column was
equilibrated and iodide eluted with 0.015 M NaOH, 0.5 M
[125j]ip^ was eluted with 0.1 M NaOH, 0.005 M NaCl.
NaCl.
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free iodide by about 1% per month.

The [ 125 I]T3 solutions

used for binding assays had less than 5% iodide.
3.3

T3 Adsorption During Manipulations
Triiodothyronine handling is difficult due to the

tendency of T3 to adsorb to most surfaces,

With the use

of polypropylene micropipettor tips and polypropylene
Eppendorf tubes or even with siliconization of the
equipment used in the preparation of stock T3 solutions,
there is a significant loss of T3 to the tips and tubes.
Only 70 ± 2% of the T3 expected to be transferred is
actually "free" to the extent that a subsequent aliquot
can transfer it to another, tube.

Pipettor tips retain 5.2

± 0.5% of the T3 taken up into them, while Eppendorf tubes
remove from solution 26 ± 2% of the T3 placed in them,
relatively independent of the volume,

Therefore, the

amount transferred in all serial dilutions of T3 must be
corrected to 7Q% of that expected for each transfer made.
An understanding of this phenomenon provides an
explanation for the downward curvature in plots of
saturation of binding as the level of T3 is increased
beyond the physiological range.

At high levels of T3, the

cold T3 added (lO"6 to 10~4 M) to determine nonspecific
binding begins to compete with nonspecific adsorption of
T3 to the incubation tube resulting in a significantly
greater amount of "free" T3 (both labeled and unlabeled).
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This decrease in nonspecific adsorption of labeled ligand
causes both the total and nonspecific binding to be
increased.

As T3 levels are increased above 10“4 M, T3

precipitates out of solution causing nonspecific binding
to rapidly increase above the level of "total” binding,
eventually yielding negative values for specific binding.
If a 500-fold excess of cold T3 is utilized in determining
nonspecific binding, 5 nM [ 125 I]T3 in the total binding
tube will have a corresponding nonspecific binding tube
with 2.5 jaM unlabeled T3, and thus may exhibit
disproportionately high binding in the nonspecific tube.
Therefore, analysis of the binding curve was examined only
in the region below 5 nM T3 (which spans the physiological
range) and previously confusing results above that level
can be properly ignored as an artifact.
3.4

Isokinetic Sucrose Gradient Sedimentation
Sedimentation of the T3 receptor after incubation

with [ 125 I]T3 gave broad bands in both radioactivity and
absorbance at 280 nm.

The sedimentation coefficient of

1.9 ± 0.2 S obtained for both control (n=7) and diabetic
(n=4) mice is at variance with that of 3.4-4.5 S reported
for rat liver.

A protease inhibitor (Trasylol) was used

during the sedimentation procedure but not throughout the
isolation procedure.

Although Latham et al. (1976) and

Perlman et al. (1982) used protease inhibitors in their
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receptor isolation procedures, Barsano and DeGroot (1983)
and Samuels et al. (1980) did not, yet obtained similar
values.

Thus, it is unlikely that the low sedimentation

coefficient obtained in this study is due to degradation
of the mouse receptor from a failure to inhibit
proteolysis during isolation.

Furthermore, the molecular

weight determination on the mouse receptor did not
indicate a reduction in the mass of the mouse receptor as
compared to the rat.
Only one peak was present in each sample indicating
that there is only one form of the receptor in the
preparation.

A t-test did not indicate a significant

difference between controls and diabetics.

Thus, any

difference between the control and diabetic receptor is
not great enough to cause a difference in the
sedimentation coefficient.

Figure 4 shows an isokinetic

sucrose gradient sedimentation profile.

The small upward

trend in the control under the 3.6 S peak for ovalbumin
was not invariably present in other profiles.
3.5

Isoelectric Focusing of the [125I]T3-Receptor Complex
Isoelectric focusing on Immobiline narrow range pH

gradients resolved receptor bound T3 from free T3 at
isoelectric pH's (pi's) of 6.64 ± 0.02 (n=5) for controls
and 6.64 ± 0.05 (n=3) for diabetics (Figure 5).

As might

be expected from the observed values, a t-test indicated
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Figure 4:
Sample profile from isokinetic sucrose gradient
sedimentation of the [ 125 I]T3-receptor complex. Fraction
1 is the top of the centrifuge tube and fraction 42 is the
bottom of the tube, The absorbance at 280nm is of
ovalbumin (3.6 S) run in a separate tube.
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Figure 5:
A representative sample of isoelectric focusing of the
f 125 I]T3-receptor complex on a linear pH gradient
Immobiline gel. The pH range is 5.873 to 6.842. Only one
major peak was found consistently in all the gels.
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no significant difference in the pi values for the T3receptor complex between the two groups.

Immobiline gels

are capable of resolving proteins differing in their pi by
as little as 0.001 pH units indicating a high degree of
similarity in pi for the control and diabetic receptor
preparations.
3.6

Scatchard Analysis Binding Constants
Although Scatchard plots are not rigorously correct

in a system which does not reach equilibrium, the
constants obtained from such a treatment have value in
making comparisons between similar groups.

Figure 6

demonstrates the close correlation between the specific T3
binding data and the curve calculated from Scatchard
analysis of the data.

It also shows that T3 binding by

the receptor preparation is saturable, supporting the
conclusion that a T3 receptor is present.

Table 3

summarizes the constants found for normal C57BL/KsJ,
heterozygous (db/m), and diabetic (db/db) mouse hepatic
nuclear T3 receptors,

Figure 7 re-emphasizes a comparison

between controls and diabetics.

The average

of (1.3 ±

0.8) x 10 -10 M (n=8) for controls is significantly less
than that of (8.7 ± 10.4) x 10 -10 M (n=4) for the diabetic
animals.

The statistical significance was determined by

comparing the slope of the regression line in Scatchard
plots using the method of Dixon and Massey (1969) as

83

Figure 6:
T3 binding saturation curve for the control and diabetic
hepatic nuclear T3 receptor preparation. Quadruplicates
were run at each T3 concentration, The curves are the
expected binding derived from the constants calculated by
Scatchard analysis of the data. The difference in maximum
binding capacity between the control and diabetic mice was
not significant when normalized to binding per mg DNA.
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Figure 7:
Scatchard plot of T3 binding to the control and diabetic
hepatic nuclear T3 receptor preparation, The lines
represent the best fit as determined by linear least
squares regression assuming all error is in the Y axis.
The difference in maximum binding capacity between the
control and diabetic mice was not significant when
normalized to binding per mg DNA.
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Table 3:
Scatchard plot binding constants for normal, heterozygous
(db/m), and diabetic (db/db) mouse hepatic nuclear T3
receptor preparations. Control and diabetic T3 receptor
preparations in the same row were assayed in pairs using
the same buffer and stock solutions while each separate
row used separate batches of buffers. MBC is moles/mg
protein. Age is in weeks, Asterisk (*) signifies animals
fasted for 24 hours prior to killing.
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outlined in the Appendix.

In each comparison, the

probability of controls and diabetics being from the same
distribution and differing only due to random variation
was less than 5%.

If both control and diabetic receptors

were in fact the same, then each binding assay would be an
independent sample of the population.

The probability

that one would see similar differences in the slope over
many experiments due to randomness alone would then be the
product of the probabilities obtained by the method of
Dixon and Massey (1969) for each matched pair,

In this

manner, the overall probability of getting the above
results is 2 X 10 -8 , indicating that the two groups are
not the same.

The difference in the

values was also

determined to be statistically significant by a one tailed
t-test (p<0.01).

Since nuclear T3 levels are about 10

times greater than cytoplasmic T3 levels which in turn are
10 times greater than plasma free T3 levels, the nuclear
T3 level is about 10 -10 M (Surks et al., 1975; Pardridge &
Landaw, 1987).

If the free T3 concentration in the

nucleus were 10”10 M, the above Kd values would predict
43% saturation of the receptor in heterozygotes but only
10% saturation of the T3 receptor in diabetics.
Although the maximum binding capacity of (5.4 ± 1.9)
x 10 -13 moles/mg protein in the assay for controls and
(2.7 ± 1.6) x 10 -13 for diabetics seem to be dissimilar.
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they must be normalized, prior to comparison, to the
amount of nuclear material per animal since the T3receptor complex has its effects on the transcription of
DNA.

When the maximum binding capacity was scaled to the

amount per liver, the controls demonstrated (7 ± 3) x
10”13 moles/liver which was not statistically different
from (11 ± 8) x 10 -13 in diabetics.

Similarly, when

maximum binding capacity was calculated on the basis of
liver DNA content, no significant difference was found
between the values of (4.6 ± 3.3) x 10 -13 moles/mg DNA for
controls and (3.2 ± 4.6) x 10 -13 for diabetics.
3.7

Kinetics of Association and Dissociation
Although Scatchard analysis has been shown above to

demonstrate a difference between the Kd for T3 of controls
and diabetics, it can not distinguish whether the
difference is due to the receptor, or if the "inapparent,
nonspecific binding” suggested by Seelig et al. (1981) is
actually causing the difference,

Another method to

determine the extent of ligand-receptor dissociation is to
observe the rate at which labeled ligand is lost from the
receptor with time,

This method is valuable in that it

ignores any "inapparent, nonspecific binding" allowing the
T3-receptor dissociation to be examined independently.
Association half-lives of 8.5 hours for controls
(n=3) and 6.2 hours (n=l) for diabetics are not
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significantly different (compare the slopes in Figure 8).
However, the half-life of labeled ligand binding in the
presence of excess unlabeled ligand is significantly
greater for controls, 101 ± 22 hours (n=10) versus 70 ± 21
hours for diabetics (n^S, p<0.04, see Table 4).

Figure 9

illustrates the association of T3 with the control
receptor preparation as well as the dissociation of T3
from the control receptor preparation, while Figure 10
illustrates the T3 association and dissociation for the
diabetic receptor preparation.

Figure 11 is a combination

of the dissociation data from Figures 9 and 10 plotted on
the same scale to facilitate comparison of the slopes.
The association data indicates that the Kd should be 2 x
10“10 M and the half-life for dissociation should be 6
hours.

The predicted Kd agrees well with the observed K^;

however, the half-life for the dissociation of the T3receptor complex does not agree with the observed halflife.

This indicates that the binding conditions are not

equilibrium binding conditions.
3.8

Molecular Weight Estimation by G-100 Chromatography
The receptor molecular weight was estimated by G-100

Sephadex chromatography to be 65,000 ± 3,000.

Denaturing

conditions were not used in order to allow [125I]T3
binding to act as a label for the receptor during elution.
Since the conditions were not designed to give a random
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Table 4:
Half-lives for the dissociation of the hepatic nuclear T3receptor complex for normal, heterozygous (db/m), and
diabetic (db/db) mice. The data for normals and
heterozygotes were combined to form the control group.
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Figure 8:
The initial portion of the association curve between T3
and the hepatic nuclear T3 receptor preparation
transformed into a linear form. The Y axis is on a
logarithmic scale. The lines represent the best fit as
determined by linear least squares regression assuming all
error is in the Y axis.
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Figure 9:
The association and dissociation curves for the control
hepatic nuclear T3 receptor preparation, Open circles
give the association curve while open squares, triangles,
and diamonds are the data points for the three
dissociation curves. The Y axis plots on a logarithmic
scale the percent of the tracer ligand added that became
bound. The lines represent the best fit as determined by
linear least squares regression assuming all error is in
the Y axis.
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Figure 10:
The association and dissociation curves for the diabetic
hepatic nuclear T3 receptor preparation. Open circles
give the association curve while open squares, triangles,
and diamonds are the data points for the three
dissociation curves. The Y axis plots on a logarithmic
scale the percent of the tracer ligand added that was
bound. The lines represent the best fit as determined by
linear least squares regression assuming all error is in
the Y axis.

99

O

O

punog ^uaojag

100

Figure 11:
The dissociation curves for both control and diabetic
hepatic nuclear T3 receptor preparations. Filled symbols
are the data points for controls while open symbols are
the data points for diabetics. The lines represent the
best fit as determined by linear least squares regression
assuming all error is in the Y axis. The solid lines are
the dissociation of the control T3-receptor complex, the
dotted lines are the dissociation of the diabetic T3receptor complex.
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coil configuration, the conformation of the receptor
molecule may have played a significant role in the value
obtained.

Thus, this value is tentative until the

receptor can be detected in a denatured state in which the
Stokes radius is known to relate more closely to molecular
weight.
3.9

Estimation of Free [125I]T3 by Receptor Binding
After 48 hours of incubation with (1.29 ± 0.04) x

10”13 moles of T3 at 4°C, the tubes with one aliquot of
receptor specifically bound (2.91 ± 0.07) x 10 ~14 moles of
[

125 I]T3 (n=5).

The tubes with two aliquots of the

receptor preparation, one added immediately and the other
added after 24 hours of incubation, specifically bound
(5.0 ± 0.1) x 10 -14 moles of [ 125 I]T3 (n=5).

If T3 were

free to interact with the additional receptor aliquot,
then the binding for the tubes with two aliquots should
have been 5.14 x 10 -14 moles when

is 1.3 x 10”10 M.

Thus, 98 ± 2% of the T3 was able to interact with the
second receptor aliquot indicating that under these
conditions, T3 can be considered to be free in solution.
The tubes with only one aliquot of the receptor
preparation were used to determine the MBC.

This value

was doubled for the tubes containing two receptor
preparation aliquots and used to calculate the expected T3
binding in the tubes with two receptor preparation
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aliquots.

Free T3 was calculated as the total T3 added

minus the specifically bound T3 minus the nonspecifically
bound T3 minus the T3 left on the walls of the incubation
tube.

4. Discussion
4.1 The Use of Equilibrium Binding Analysis
Seelig et al. (1981) and all other workers have used
Scatchard plots extensively.

In order to make direct

comparisons of the data in this study with the results
reported in the literature, it is helpful to use the same
method of analysis.

However, the fact that many people

adopt a method does not assure that the method is valid.
Equilibrium binding analysis such as that used by
Scatchard (1949) is based on the assumption that binding
is measured at equilibrium and is reversible.

The

conclusion of Seelig et al. (1981) that this assumption is
not valid for T3 at 0°C would appear to invalidate
Scatchard plots as a method of describing the thyroid
hormone receptor binding system.

However, non-equilibrium

conditions do not necessarily negate the significance of
the results of equilibrium type analysis, especially when
used to compare two similar groups of animals.
As mentioned in the Introduction and Results
sections, Seelig et al. (1981) concluded that the
interaction between T3 and nonspecific binding sites over
a 24 hour time period demonstrates essentially
irreversible binding.

Thus, after incubating excess T3

with the T3 receptor preparation, all the T3 became
associated with either the receptor or with nonspecific
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binding sites.

The addition of more T3 receptor to the

equilibrated system demonstrated the irreversibility of
binding to nonspecific sites in that there was no increase
in the specific T3 binding.

If a transfer of T3 from the

nonspecific sites to the added T3 receptor protein was
possible, the specific T3 binding should have increased.
Although Seelig et al. (1981) continue to use
Scatchard plots in spite of these concerns, a more
reassuring fact to consider is the binding of T3 analogs.
As reviewed by Samuels (1983), there is an excellent
correlation between the relative binding constants
obtained through equilibrium binding analysis and the
relative biological activity of T3 analogs,

The binding

constants determined from Scatchard plots all demonstrate
a direct relationship with the effects of ligand binding,
thereby confirming the value of this method.
Another point in favor of utilizing equilibrium
binding analysis to understand the binding of thyroid
hormone is that the kinetic model proposed by Seelig et
al. (1981) predicts essentially the same binding as
predicted by Scatchard plots.

Thus, even if Seelig et al.

(1981) are correct in their conclusion that Scatchard
plots are invalid, the method nevertheless accurately
predicts the binding behavior,

It is important to

recognize that if Seelig et al. (1981) are correct, the
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constants obtained are apparent equilibrium binding
constants and may not reflect what binding would be under
true equilibrium conditions.

But, solely on the basis of

fitting the data, the binding constants are useful for
predicting and comparing ligand binding.
apparent

Thus, the

values of (1.3 ± 0.8) x 10 -10 M for controls

and (8.7 ± 10.4) x 10 -10 M for diabetics can be used to
demonstrate a significant difference in the level of T3
binding to the nuclear T3 receptor in these two groups
under physiological T3 concentrations.
One concern raised by Seelig et al. (1981) remains
which must be considered when comparing binding constants
for thyroid hormones.

The proposed "inapparent,

nonspecific sites” sequester T3 making it unavailable to
the receptor itself, yet this T3 appeared in their assay
as free T3.

If one were to compare two receptor

preparations with identical receptor binding
characteristics, but with different amounts of inapparent,
nonspecific binding, the increased inapparent binding
would lower the amount of free T3 available to interact
with other binding sites.

This would lower the amount

bound to the receptor and other nonspecific sites,

Since

the reason the sites are "inapparent" is that they do not
show up in the assay as nonspecific binding, the effect
would be to lower total binding, including both
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nonspecific and specific binding.

Thus, the binding curve

would in effect be shifted to the right.

Since

nonspecific binding increases linearly with increasing
ligand concentration, the effect would be equivalent to a
linear transformation of the X axis of a saturation plot.
The maximum binding capacity would not be affected, but Kd
would be increased.

A difference in the level of

"inapparent, nonspecific binding" somewhat greater than
the error in binding measurements would lead to the
conclusion that the two groups differed in their Kd even
though the receptors were identical.
Since this study used nitrocellulose filtration
rather than a T3 binding resin to separate bound from free
T3, there is probably less removal of T3 from weakly bound
nonspecific sites.

Thus, the problems associated with

"inapparent, nonspecific sites" would be diminished.
However, as a safeguard against falsely stating the
binding of controls to be different from that of
diabetics, the dissociation of T3 from the receptor was
studied to further characterize any alterations in the
interaction of the receptor with T3.
Alterations in "inapparent, nonspecific binding" only
affect the amount of T3 available to interact with other
nonspecific binding sites and with the receptor,

By

incubating labeled T3 with the receptor preparation until
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bound T3 levels reach a plateau and then blocking
reassociation of dissociating labeled T3 by adding excess
unlabeled T3, the rate of the decrease of specific binding
should not be affected by a lower initial level of binding
due to "inapparent, nonspecific binding”,

Since the

dissociation half-life for controls (101 ± 22 hours) was
significantly greater than that for diabetics (70 ± 21
hours), one can conclude that the T3-receptor interaction
is weaker in diabetic liver.
of the larger

This reinforces the validity

for diabetics reported in this study.

Thus, although the basic assumptions for equilibrium
binding analysis have not been demonstrated, Scatchard
plots are used in this study with confidence that the
binding constants obtained, in conjunction with the
dissociation half-lives, can be used to compare receptor
binding.
4.2

The Assumption of Free T3
Although many workers studying thyroid hormones

assume that T3 is free in their binding assay solutions.
this is only partially true.

As previously mentioned, at

0 ° C Seelig et al. (1981) demonstrated that no free T3 was
available as determined by the lack of additional specific
T3 binding after addition of more T3 receptor preparation.
This indicates that all the T3 interacted with the
components in the original incubation mixture in such a
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fashion that it was not available for binding to the added
receptor.

However, Yagura and Walfish (1982) demonstrated

that after incubation at 4°C, 90% of the resin-absorbable
T3 could cross a dialysis membrane,
the T3 is free in solution,

This indicates that

They concluded that under

their conditions for binding (4°C) T3 would be expected to
interact with additional receptor.

This finding appears

to contradict the results of Seelig et al. (1981).

Yagura

and Walfish (1982) stated this information as supported by
unpublished data, but they did not clarify how this
finding was determined.

If they actually measured the

ability of T3 to equilibrate across a dialysis membrane
after resin binding, it would not have any bearing on the
availability of T3 to bind to the receptor since the point
made by Seelig et al. (1981) was that the resin strips T3
off the ”inapparent, nonspecific sites”,

It should be no

surprise that when T3 is removed from any interaction with
binding sites it is then free to cross a dialysis
membrane.

With the data presented one cannot properly

evaluate the results of Yagura and Walfish (1982) and can
only tentatively conclude that the difference in binding
conditions may have led to the contradictory results.
This conclusion is supported by the results in this study
demonstrating 98 ± 2% of the expected binding to a second
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aliquot of the receptor preparation under conditions
similar to those used by Yagura and Walfish (1982).
However, as stated in the results, T3 was bound
nonspecifically to all the surfaces used in the assay of
T3 binding including glass, siliconized glass.
polystyrene, and polypropylene.

In serial dilutions, free

T3 decreased to 70% of the expected value with each
dilution step.

Thus, the concentration of free T3 is

decreased by 30% due to binding to glassware alone,

After

correcting for T3 adsorption to glassware, the level of
nonspecific T3 binding to the receptor preparation in the
presence of excess unlabeled T3 was only 3% of the
remaining T3.

Since most of the incubated T3 passes

through the filter, it should be free in solution.

This

would also support the conclusion of Yagura and Walfish
(1982) that significant amounts of T3 are free.
The value of 98% of the expected increase in binding
for the addition of a second aliquot of the receptor
preparation was calculated without correcting for
nonspecific adsorption to the incubation tube,

It appears

that the T3 initially adsorbed to the incubation tube,
which in a serial dilution would not be seen as free in
solution, is nevertheless able to interact freely with the
receptor.

Thus, only in serial dilutions does the

correction have to be made for adsorption to glassware.

Ill
The T3 adsorbed to the incubation tube in receptor binding
studies can be considered as free in solution.
4.3 Significance of the Maximum Binding Capacity
Differences Between Controls and Diabetics
Although the difference between the T3 MBC of (4.6 ±
3.3) x 10 -13 moles/mg DNA for controls versus (3.2 ± 4.6)
x 10 -13 moles/mg DNA for diabetics did not achieve
statistical significance, a difference might be expected
on a theoretical basis.

Glucagon administration to

diabetic rats lowers the MBC (Dillmann et al., 1978) as
well as lowering the serum T3 in dogs (Kabadi & Dragstedt,
1987) .

Although basal circulating levels of glucagon are

normal in the diabetic mouse, the control of glucagon
secretion is altered (Bray & York, 1979).

Arginine

stimulates excessive glucagon release and glucose does not
suppress glucagon release.

Thus, periodic hypersecretion

of glucagon could occur with a corresponding decrease in
the MBC for T3.
The failure to demonstrate a statistically
significant difference does not mean the parameters
compared are actually identical.

An increased sample size

may in the future demonstrate a difference in the MBC
between controls and diabetics.

In any case, the data

presented here indicate that any difference found would be
small.

It appears that either a hypersecretion of
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glucagon is not present or the levels are not high enough
to significantly lower the MBC in the diabetic C57BL/KsJ
mouse.
4.4 The Diabetic Mouse
Recessive Genes

4.4.1

Diabetes in the mouse is a recessively inherited
disorder.

Recessive diseases are generally the result of

an alteration in a single DNA base pair.

Thus, diabetes

in the mouse could have resulted from a single base pair
change.

If so, the alteration to the protein encoded by

that gene should explain all the symptoms of the syndrome.
The T4 51-monodeiodinase

4.4.2

If one altered protein is the root of the syndrome,
then the symptoms should suggest its identity.

One change

observed in the diabetic mouse is an increase in serum T3
and a decrease in serum T4 (Fehn, 1983).

Accordingly, the

5'-monodeiodinase was investigated in the hope that it
might be the protein whose gene was altered.

Utilizing

the method of Chiraseveenuprapund et al. (1978), liver and
kidney homogenates were assayed for the conversion of T4
to T3.

However, no difference was found in the kinetic

parameters of the 51-monodeiodinase In vitro between
diabetic and control mice (Richard Fehn, personal
communication).
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Obesity

4.4.3

Another consequence of the diabetic mutation is
obesity.

One means by which an obese state can be induced

is to decrease the basal metabolic rate,

Since the

maintenance of ion gradients by the Na+-K","-ATPase pump
comprises a significant portion of the energy expended on
the basal metabolic rate, it has been investigated in a
number of syndromes characterized by obesity.
Studies on the genetically obese ob/ob mouse
utilizing ouabain to block the Na+-K+-ATPase pump have
demonstrated that the obese mouse has a reduction in
energy expenditure on Na+-K+ transport (Guernsey &
Morishige, 1979).

More relevant to T3 receptor studies

however is their finding that these mice demonstrate
decreased Na+-K+-ATPase activity due in part to a
decreased nuclear T3 maximum binding capacity.
Furthermore, Khan et al. (1986a) demonstrated a parallel
progression in both obesity and the decrease in the number
of T3 receptors.

They further suggest that the decrease

in T3 receptors is the primary cause of the obesity,

The

genetically obese Zucker fatty rat also shows a decrease
in the MBC of T3 as one progresses from normal to
heterozygous to homozygous for the fatty gene (Goldberg et
al., 1988).
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A similar effect mediated by a different mechanism
was proposed by Hillgartner and Romsos (1987).

They did

not report reduced numbers of T3 receptors in obese mice,
but still found decreased nuclear T3 binding.

They

suggested that decreased nuclear T3 binding was the result
of decreased transport of plasma T3 to the nucleus because
of altered membrane fluidity.

Another example of an

alternative mechanism to achieve similar results is
reported by Tulp and McKee (1986).

They proposed that the

cause of obesity in LA/N-cp rats is related to decreased
T4 to T3 conversion.

Thus, there is widespread support

for a causal role of altered T3 binding in obesity.
Nevertheless, there is not universal support for T3
involvement in all obesities.

Anselmet et al.

(1984) did

not find any alteration in T3 binding parameters in cell
lines derived from the obese mouse.

In addition, other

mechanisms aside from decreased T3 binding may lead to
obesity.

In one study, the Zucker fatty rat demonstrated

a reduced T3 binding capacity in only 50% of the obese
animals indicating that other factors could be involved
(Khan et al., 1986b).
4.4.4

T3 Binding in Obese and Diabetic Mice
Since the obesity related reductions in T3 binding

were proposed by some authors to be the cause of the
obesity, a comparison to the diabetic mouse would indicate
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whether the increase demonstrated in the Kd in the
diabetic mouse is great enough to influence its obesity.
The T^-receptor complex is the form that leads to the
effects of T3 so the number of complexes per cell should
be the parameter that is most closely related to obesity.
To compare the various obese states, the saturation level
for each class of obese animals was estimated from their
T3 binding constants assuming that the nuclear T3
concentration was 10”10 M.

The percent saturation was

normalized by multiplying it by the number of binding
sites per cell in C57BL/KsJ controls (-5000).

The

controls would have roughly 2000 T3-receptor complexes per
cell, the obese LA/N-cp rat would have 1500, the obese
mouse would have 1000, and the diabetic mouse would have
500.

Since the diabetic mouse would have the lowest

relative number of T3-receptor complexes, it would be more
likely to display obesity due to reduced T3 effects than
would the obese mouse.

Thus, the difference in the

saturation level of the T3-receptor complex of 10% in
diabetics versus 43% in controls as reported in this study
is a significant reduction in terms of its expected effect
on the animal.
4.4.5

T3 Resistance
The obesity, cold intolerance, and elevated serum T3

seen in the diabetic animal are consistent with a
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reduction in thyroid hormone effects.

Having suggested

that the obesity of the diabetic mouse may be directly
related to the reduced level of T3 binding to the nuclear
T3 receptor, it may be further suggested that all of the
diabetic symptoms may be due to a change in the receptor
and that the gene which was modified is that of the T3
receptor.

However, clinical syndromes which demonstrate

thyroid hormone resistance do not display the symptoms of
diabetes.

As previously mentioned, Refetoff (1982) did

not observe any diabetic symptoms in patients with thyroid
hormone resistance.

On the other hand, the lack of

correlation between thyroid hormone resistance and
diabetes in man does not exclude the possibility of a
connection in the mouse.

However, it does require that

the correlation be solidly established if one is to use it
to explain the aberrant physiology in mice.
4.4.6

Other Alterations in the Diabetic Mouse
Adipsin is a serine protease homolog secreted by

adipose cells which may function as a regulatory molecule
(Flier et al., 1987).

Glucose and high insulin levels

decrease the amount of adipsin while mild diabetes has the
opposite effect.

In the C57BL/KsJ (db/db) mouse adipsin

levels are extremely low (Flier et al., 1987).

Since

adipsin may be a regulatory molecule and it has altered
expression in the diabetic mouse, it is potentially a
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modulator of the diabetic state as well.

On the other

hand, the low adipsin levels could be merely a reflection
of the high levels of insulin which are transiently
present in the diabetic mouse,

Further research is

warranted to establish adipsin's significance.
4.5

Proposed Model for the Diabetic Mouse
If the diabetic mouse has normal free T3 levels and

if an altered T3 receptor gene is at the core of the
diabetic mutation, then the following sequence of events,
a modification of the events proposed by Bray and York
(1979), are a reasonable model for the development of the
diabetic state which is consistent with the currently
available data.

Decreased T3 binding by the nuclear

thyroid hormone receptor leads to decreased Na+-K+-ATPase
activity.

This in turn leads to hypersecretion of insulin

in response to glucose stimuli.

Decreased ion transport

also leads to decreased re-uptake of norepinephrine in the
hypothalamus, thereby altering food intake regulation and
leading to hyperphagia.

Hyperinsulinemia leads to

hyperlipogenesis and eventually to down-regulation of
insulin receptor number.

As obesity develops due to

increased food intake coupled with lower energy
expenditure on the maintenance of ion gradients, decreased
locomotion furthers the drive towards obesity.
continues to supply glucose by accelerating

The liver
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gluconeogenesis, furthering the impetus for high insulin
output, eventually leading to beta cell exhaustion.

The

51-monodeiodinase shifts more T4 to T3 in an attempt to
overcome the thyroid hormone resistance leading to
increased T3 levels which inhibit thyroid function.

Serum

T3 binding proteins then increase and achieve
normalization of free T3 levels.
This is not the only model possible nor does
decreased binding of thyroid hormones need to be an
initial event.

It is quite possible that another factor

released from the mutated gene could lead to a different
cascade of events.

Post-translational modifications of

the receptor or alterations in binding cofactors, such as
the histone fractions known to modify T3-receptor binding
could yield data such as that presented here yet avoid any
requirement for the receptor per se to be altered,

Recent

advances in the genetics of the thyroid hormone receptor
suggest that there may be multiple forms for the T3
receptor which may have different T3 affinities (Thompson
et al., 1987).

DNA probes for the thyroid hormone

receptor gene indicate that as many as 5 thyroid hormone
receptors may exist,

Altered overall binding could be the

result of altered levels of receptor subtypes which have
varying affinities for T3.
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4.6

Indications of a Change in the T3 Receptor Gene
If there were a mutation in the gene coding for the

nuclear T3 receptor one might see evidence in some
physical parameter of the nuclear T3 receptor which would
be altered as well.

Obviously, binding might be

different, but if other characteristics were also changed
one would be reasonably certain that significant
alterations were made to the receptor.

Therefore, the

isoelectric point and sedimentation coefficient were
determined in this study.

However, neither parameter

demonstrated a significant difference from controls
indicating that the receptor was not severely altered.
The receptor*s molecular weight of 65,000 was higher than
the 52,000 predicted by the sequence of the human c-erb-A
gene which encodes the human thyroid hormone receptor
(Weinberger et al., 1986).

Gruol and Kempner (1982) used

radiation inactivation and target theory to demonstrate
that the effective mass of the receptor in rat is 59,000
daltons.
It has been shown that other molecules are present in
vivo which are involved in determining the level of T3
binding (Anselmet et al., 1983? Bismuth et al., 1985).
Accordingly, the use of relatively crude receptor
preparations may have advantages over more highly purified
preparations in that these binding cofactors may be

120
retained with the receptor during partial purification as
indicated by the large molecular weight determined in this
study.

By retaining the receptor complex in a state more

like that seen in vivo, the binding constants obtained are
more likely to reflect the level of binding in the cell.
4.7 Future studies
Determining the binding constants in diabetic mice as
they develop, especially at ages from birth until sexual
maturation, may reveal dynamic alterations in T3 binding
which, if they were to parallel the development of the
diabetic symptoms, would suggest that altered T3 binding
might be closely involved,

More extensive examination of

the kinetics of ligand-receptor association might also
reveal interesting findings, since the relative difference
between the association half-lives of controls and
diabetics is almost the same as the relative difference
between the dissociation half-lives.

In this study, more

data were collected on the dissociation half-lives, which
caused the difference between controls and diabetics to
become statistically significant when in fact both aspects
of ligand-receptor interaction may be affected.
Further purification of the receptor to homogeneity
would aid in determining the molecular weight of the core
receptor under denaturing conditions, as well as in the
chemical characterization of the T3 receptor to see if
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there are any physical changes between controls and
diabetics.

Differences might be expected in the amino

acid composition, level of glycosylation, or in the
presence or composition of a binding cofactor,

Since the

sequence of a human thyroid hormone receptor is known,
portions could be used to probe for the mouse receptor.
With the mouse gene in hand, direct studies on the
sequence of the diabetic and normal receptor gene would
give a straightforward answer to the question of whether
any mutation occurred in the receptor gene.
Although the nuclear T3 receptor has been referred to
extensively as the only true receptor, that has yet to be
proven.

Further research needs to be conducted to

demonstrate conclusively that this protein is in fact a
necessary link in the transduction of the T3 signal and
the expression of the diverse effects of thyroid hormones.
The mechanism of action for thyroid hormones is also
somewhat speculative at this time and could benefit from
more investigation,

A final goal would be the complete

determination of all the mechanisms whereby T3 effects the
cell, including cells exhibiting perturbations such as
diabetes.

5•
5.1

Appendix

Derivation of the Equations for Multiple Lines With
One Common Slope
The derivation of the equations for many lines with a

single slope follows the concepts used in deriving the
equation for simple linear least squares regression on one
The theory of least squares regression generally

line.

assumes that all the error in experimental data is in the
Y axis.

It also assumes that the true relationship

between the X and Y axis is indeed linear.

Thus the true

line that one wishes to calculate should run through the
true mean Y for each X.

The measured Y values should have

a normal distribution scattered around the average Y due
to random variation.
Least squares analysis simply means one minimizes the
sum of the squares of the differences between the
predicted Y values and the measured Y values,

In the case

of many lines with the same slope one is trying to
determine:
(1)

Y± = mXx + b-L

(2)

Y2

= mx2 + b2

(3)

Y3

= mX3 + b3

et cetera for each line
Thus one needs to determine the value of m, b
etc.
122

b2, b3.

123
If one has j lines with n^ points in line i and with
k specifying the points in line i where i is the line
number (1 to j), the deviation of the measured

from

the predicted Y is
(4)

Yik - (mXik +

or

Yik - mXik - bi

The sum of the squares of the deviations for n^ points is
then
(5)

2(Yik - mXik - bi)2

To minimize the sum of the squares of the deviations from
all the lines let
(6)

Q = 2(Ylk - mxlk - bx)2 + 2(Y2k - mX2k - b2)2 + . .

To find the value of a variable at the maximum or minimum
of a function one takes the partial derivative of the
function with respect to that variable and sets it equal
to zero.

Solving for the variable under investigation

will give the value of that variable when the function is
at either its maximum or minimum.

Thus one must evaluate

8Q/8m, SQ/Sb^ 8Q/8b2, 8Q/8b3, etc.

Re-writing the equation

above
(7)

Q = (2Ylk2 “ 2m2XlkYlk - 2b12Ylk +m22Xlk2 + 2mb1SXlk
+ n-j^b^^2) + (EY2k2 - 2mSx2kY2k - . . .

The partial derivatives are then
(8)

8Q/8m = (-2SXlkYlk + 2mi:xlk2 + 2b12Xlk) + (-2EX2kY2k
+ 2mSx2k2 + 2b25:x2k) + (. . .

(9)

8Q/8b1 = -22Ylk + 2m2xlk + 2n1b1
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(10)

8Q/8b2 = -22Y2]c + 2mEX2k + 2n2b2

(11)

8Q/8b3 = —22Y3k + 2m2X3k + 2n3b3
et cetera

Setting the partial derivatives equal to zero and
simplifying gives
(12)

0 = (-2XlkYlk + m2Xlk2 + b^X^) + (-2X2kY2k +
m2x2k2 + b22x2k) + (. . .

(13)

0 = _2Ylk + m2xlk + n-^b^^

(14)

0 = _2Y2k + in2x2k + n2b2

(15)

0 = -2Y3k + m2X3k + n3b3
et cetera

Solving equations 13-15 the for the intercepts b

b2, b3,

etc. to get equations 16-18 and substituting into equation
12 yields equation 19.
(16)

b1 = (2Ylk - m2Xlk)/n1

(17)

b2 = (2Y2k - m2x2k)/n2

(18)

b3 = (2Y3k - m2x3k)/n3
et cetera

(19)

0 = (“2xlkYlk + m2Xlk2 + 2Xlk[2Ylk - m2Xlk]/n1) +
^”^X2kY2k + m^X2k2 + ^X2k^Y2k ” m^x2k^/n2^ +
(.

Rearranging
(20)

2XlkYlk + ^x2kY2k + • • • ~
m2xlk2 + 2xlk2Ylk/n1 — m(2x^k) ^/n-^ + m2x2k
^x2k^Y2k/n2 “ Itl(^x2k^2//n2 + . .

+
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Isolating the terms with the slope (m)
(21)

2xlkYlk ” 2xlk2Ylk/nl + 2x2kY2k “ 2x2k2Y2k/n2
+ .

.

. =

m2xlk2 - m(2xlk)2/n1 + m2X2k2 - m(2X2]C)2/n2
+ .

.

.

Factoring out m
(22)

2XlkYlk

- 2xlk2Ylk/n1 + 2x2kY2k - 2x2k2Y2k/n2

m(]Sx^j^2 — (2xlk) 2/ni + 2x2k2 ~ (2X2k) 2/n2
+ .

. .)

Solving for the slope (m) and combining the similar sums
(23)

j

E

ni
E X ik

i=l k=l

Yik "

m =
j

E

2

X, 2
ik

i=l k=l

With intercepts (b^) at
(24)

ni
ni
Ex
E Y
k=l ik" m k=l ik
ni

j
ni
ni
E
XE
Y
2
i=l k=l ^ k=l ik
ni
j

E
i=l

ni
,
( 2^ )2
k=l K
ni
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5.2

Sample Calculation
Assume the following 3 data sets are the data points

for 3 lines which should have the same slope.
X1

Y1

X2

Y2

X3

Y3

1
2
3
4
5

2
4
6
8
10

1
2
3
4

3
5
7
9

1
2
3

7
9
11

The following are calculated
X1

Y1

X2

XY

X2

Y2

X2

XY

X3

Y3

X2

XY

1
2
3
4
5
Sums
15

2
4
6
8
10

1
4
9
16
25

2
8
18
32
50

1
2
3
4

3
5
7
9

1
4
9
16

3
10
21
36

1
2
3

7
9
11

1
4
9

7
18
33

30

55

110

10

24

30

70

6

27

14

58

(2x)2
100

225

36

Evaluating the first complex summation in equation 23

ni
2 Xik Yik
i=l k=l
j

2

For i=l the sum of XY for all the 5 points is 110, for i=2
the sum of XY for all the 4 points is 70, and for i=3 the
sum of XY for the 3 points is 58.
110 + 70 + 58 = 238.

Evaluating the second complex

summation in equation 23
ni
2i
2 Y
2 X
i=l k=l ik k=l ik
ni
j

2

Thus the overall sum is
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For 1=1 the sum of X is 15, the sum of Y is 30, and n=5
thus the term for i=l is 15x30/5 = 90.

For i=2 one

calculates 10x24/4 = 60; for i=3, 6x27/3 = 54.

The sum

for all values of i is then 90 + 60 + 54 = 204.
Evaluating the last two complex summations in a similar
fashion yields the following expression for the four
complex summations:
(238 - 204)/(99 - 82) = 34/17 = 2
The intercept b-j^ is then (30 - [2 x 15])/5 = 0
b2 = (24 -[2 x 10])/4 = 1
b3 = (27 - [2 X 6])/3 = 5
Thus the 3 equations for the 3 data sets are
Y = 2 x X + 0
Y = 2 x X + 1
Y = 2 x X + 5
5.3

Comparison of Two Slopes as Described by Dixon and

Massey (1969)
Assuming the samples are linear, the slopes (m-^ and
m2) are calculated for the two samples by linear least
squares regression.

If sxl2 and s^2 are the variances of

the X's and Y's in the first sample and sx22 and Sy22 are
the variances of the X's and Y's in the second sample.
then the unbiased
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estimates of the variances about the population regression
lines are
s2 yl.x

(Syl2 - m12sxl2) (n-^ - l)/(n1 - 2)

s2 y2 .x

(Sy22 - m22sx22)(n2 - l)/(n2 - 2)

and

Assuming the population variances are equal, the pooled
variance is
s2 y.x.p =

(r^ - 2)s2yl>x + (n2 - 2) s2 y2 .x
nl + n2 - 4

And a t value can be calculated as
ml ” m2

1
(n-L “

(n2 " 1^SX22

sy.x.p
If this t value is greater than the critical t from a
table of t values, one would reject the null hypothesis
and conclude that the two slopes are different at the
probability level used in the critical t.
5.4

Propagation of Error
As described by Peters et al. (1974), assume one has

three experimentally determined, independent parameters x,
Y, and z.

If w is a function of these three parameters,

the variance in w is approximately
(dw/dx)2Vx + (dw/dy) 2Vy + (dw/dz)2Vz

If there are more parameters, the above equation can be
expanded with similar terms, one for each parcimeter.
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Since the 95% confidence limit is related to the square
root of the variance, the 95% confidence limit of w can be
estimated by the 95% confidence limits of x, y, and z.

r
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